<SEC-DOCUMENT>0001628280-15-001467.txt : 20150304
<SEC-HEADER>0001628280-15-001467.hdr.sgml : 20150304
<ACCEPTANCE-DATETIME>20150304172516
ACCESSION NUMBER:		0001628280-15-001467
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150304
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20150304
DATE AS OF CHANGE:		20150304

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		15674504

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8kclinicalearningsrelease.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>8K clinical earnings release</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s5495f649c64242bc9448a7f3f4a74dd6"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;">FORM 8-K</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CURRENT REPORT</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="51%"></td><td width="5%"></td><td width="44%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of Earliest Event Reported):</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 4, 2015 (March 3, 2015)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;">Cumberland Pharmaceuticals Inc.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________________________________________</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="0%"></td><td width="33%"></td><td width="18%"></td><td width="5%"></td><td width="11%"></td><td width="33%"></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tennessee</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">001-33637</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">62-1765329</font></div></td></tr><tr><td><font>&#160;</font></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of incorporation)</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer Identification No.)</font></div></td></tr><tr><td><font>&#160;</font></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2525 West End Avenue, Suite 950, Nashville, Tennessee</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37203</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant's telephone number, including area code:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(615) 255-0068</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">____________________________________________</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Former name or former address, if changed since last report</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s5495f649c64242bc9448a7f3f4a74dd6"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01 Other Events</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March&#160;3, 2015, Cumberland Pharmaceuticals Inc. issued a press release announcing the achievement of several clinical and regulatory milestones.  A copy of the press release is furnished as Exhibit 99.1.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s5495f649c64242bc9448a7f3f4a74dd6"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="68%"></td><td width="32%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumberland Pharmaceuticals Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">March 4, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">By: Rick S. Greene</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Name: Rick S. Greene</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Title: Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:15px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><hr></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit&#160;Index </font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.5625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="20%"></td><td width="13%"></td><td width="67%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release dated March 3, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991pressrelease-cli.htm
<DESCRIPTION>EXHIBIT 99.1 CLINICAL UPDATE
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>Exhibit 99.1 press release - clinical</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s71f2fb02e11c41b5974723130f6381a9"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:174%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="cumberlandpharmalogoa01.jpg" style="height:84px;width:370px;"></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-top:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS REPORTS</font></div><div style="line-height:174%;padding-bottom:12px;padding-top:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CLINICAL AND REGUALTORY MILESTONES</font></div><div style="line-height:174%;padding-bottom:12px;padding-top:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">- Initial Hepatoren</font><font style="font-family:inherit;font-size:12pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-style:italic;">&#32;Phase II study results</font></div><div style="line-height:174%;padding-bottom:12px;padding-top:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">- sNDA filed with pediatric data for Caldolor</font><font style="font-family:inherit;font-size:12pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup>&#160;</font></div><div style="line-height:174%;padding-bottom:12px;padding-top:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">&#32;- Phase II Boxaban</font><font style="font-family:inherit;font-size:12pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#8482;</sup></font><font style="font-family:inherit;font-size:12pt;font-style:italic;">&#32;trial underway</font></div><div style="line-height:174%;padding-top:10px;text-align:center;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NASHVILLE, TN (Tuesday, March&#160;3, 2015) - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)</font><font style="font-family:inherit;font-size:12pt;">, a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced achievement of several clinical and regulatory milestones. These developments include top-line results from the Company&#8217;s Hepatoren Phase II study, submission of a supplemental New Drug Application (sNDA) with pediatric data for Caldolor, and initiation of patient enrollment in the Boxaban Phase II clinical trial.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;The sNDA for Caldolor represents a key milestone following the conclusion of a series of important Phase IV studies for the product. We look forward to working with the FDA with the goal of adding pediatric information to the Caldolor label,&#8221; said A.J. Kazimi, Cumberland&#8217;s Chief Executive Officer. &#8220;The progress with Hepatoren and Boxaban reflect our strategy to expand our product portfolio through a pipeline of innovative products addressing unmet medical needs.&#8221;</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Hepatoren</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174; </sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ifetroban) Injection</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland completed enrollment in the first of two patient cohorts of its Phase II study of Hepatoren in patients with Hepatorenal Syndrome (HRS).  The Phase II double-blind, multi-center, randomized, controlled study evaluated the pharmacokinetics, safety and tolerability of ifetroban administered as daily intravenous doses in HRS patients. Patients were stratified based upon disease type, either Type I or Type II HRS diagnosis - with four dosing cohorts per disease type. Enrollment for Type II HRS patients was completed at the end of 2014. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Top line results from the Type II patient cohort indicate that ifetroban was overall well tolerated with no safety concerns noted.   Furthermore, the patients receiving the higher dose levels of ifetroban were more likely to experience increases in urine output, a signal of improvement in kidney function, compared to patients who received placebo. Based on these results, Cumberland will proceed with clinical development of this product candidate.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s71f2fb02e11c41b5974723130f6381a9"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Caldolor</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174; </sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ibuprofen) Injection</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland recently completed a series of Phase IV studies for Caldolor in more than 1,000 patients in over 30 leading medical centers across the U.S. These studies included evaluation of the product in both children and adults. Following the completion of these Phase IV studies, the Company submitted a sNDA to the FDA for the product.  This submission requested changes to the package insert to include pediatric data from the Company's post-marketing pediatric development program. In addition, the results from two Caldolor Phase IV adult studies were recently published and are currently available as manuscripts in the journal </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Clinical Therapeutics</font><font style="font-family:inherit;font-size:12pt;">. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Boxaban</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174; </sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ifetroban) Oral Capsule</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland recently announced an expansion of its pipeline with a new Phase II development program. The Company has begun the clinical development of Boxaban for the treatment of aspirin-exacerbated respiratory disease (AERD).  AERD is a respiratory disease involving chronic asthma and nasal polyposis that is worsened by aspirin.  It is characterized by sharp increases in inflammatory mediators and platelet activity within the respiratory system. Ifetroban, an active thromboxane receptor antagonist, may interfere with these pathways to modify the disease and provide symptomatic relief.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland has completed manufacturing of Boxaban oral capsules and received clearance from the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) submission and Phase II study associated with the product. The study has now been initiated with patient enrollment underway.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Cumberland Pharmaceuticals Inc.</font><font style="font-family:inherit;font-size:12pt;">&#32;is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's five marketed products include Acetate</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">acetylcysteine</font><font style="font-family:inherit;font-size:12pt;">) Injection for the treatment of acetaminophen poisoning, Caldolor</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">ibuprofen</font><font style="font-family:inherit;font-size:12pt;">) Injection, for treatment of pain and fever, Kristalose</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">lactulose</font><font style="font-family:inherit;font-size:12pt;">) for Oral Solution, a prescription laxative, Vaprisol</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174; </sup></font><font style="font-family:inherit;font-size:12pt;">(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">conivaptan</font><font style="font-family:inherit;font-size:12pt;">) Injection, for the treatment of hyponatremia and Omeclamox-Pak</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;for the treatment of </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">H. pylori</font><font style="font-family:inherit;font-size:12pt;">&#32;and duodenal ulcer disease. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland is developing Hepatoren</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174; </sup></font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">ifetroban</font><font style="font-family:inherit;font-size:12pt;">) Injection for the treatment of Hepatorenal Syndrome and Boxaban</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">ifetroban</font><font style="font-family:inherit;font-size:12pt;">) Oral Capsule for treatment of aspirin-exacerbated respiratory disease. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information on Cumberland&#8217;s approved products, including full prescribing information, please visit the individual product websites, links to which can be found on the Company&#8217;s website </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.cumberlandpharma.com</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Caldolor</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174; </sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ibuprofen) Injection</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Caldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever in adults. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticarial, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor.  For full prescribing information, including boxed warning, visit </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.caldolor.com</font><font style="font-family:inherit;font-size:12pt;">.</font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s71f2fb02e11c41b5974723130f6381a9"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company's most recent Form 10-K and subsequent 10-Q's as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:9px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.6015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="48%"></td><td width="3%"></td><td width="49%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investor Contact:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Media Contact:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Erin Smith</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rebecca Kirkham</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate Relations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lovell Communications</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(615) 255-0068</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(615) 297-7766</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SOURCE: Cumberland Pharmaceuticals Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cumberlandpharmalogoa01.jpg
<TEXT>
begin 644 cumberlandpharmalogoa01.jpg
M_]C_X``02D9)1@`!`0$`W`#<``#_VP!#``(!`0$!`0(!`0$"`@("`@0#`@("
M`@4$!`,$!@4&!@8%!@8&!PD(!@<)!P8&"`L("0H*"@H*!@@+#`L*#`D*"@K_
MVP!#`0("`@("`@4#`P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P``1"`#3`Z`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]]****`"B
MBB@`HHHH`****`"BBB@`HHI&=5!8]NM`"T5\X^(?VF%U?_@IYX;_`&5O#OB2
M?RM*^$NI^(/$5A!=$1F6>^LX+7S%!P65(IV&>0)<CAN?HZM:M&5)1YOM*_R(
MA4C4OR]-`HHHK(L****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
M)`&2::\@5"X(X&10`ZBO*OB!^V7\`/AO<SZ9JWQ!MM1U"V8K-I?AZ"34+F-O
M1T@#&/\`X'M_"O"OBE_P5OM_#D4B?#[X!ZA>,,A;GQ#JT5DGL=D0F<CV.T_2
MNNA@<7B&E"#U^7YDRG&*NS[':XA7K(!@X.37@'[=O_!1/]G[]A3X>7GB/XC^
M*H+K77M6.A^$;&X5KZ_EVG:-G)CCSUE8!5&>IXK\]?VC_P#@K3^VAXVM+C2_
M#OBS2O!UI)N7;X7TTBX*GLT]PTK`^Z",_2OSJ^-VLZWXGU6]\0^)M;O-2U"\
MD+W5_J%T\\\S8ZM(Y+,?J:^CRWA2=:HI8F24>J6K?EY?(\[&8[V5-N!]M_\`
M!!W]H/X@_M5_\%AOB/\`'OXHWPFU?Q%X$OIYHTSY5O']KLEC@C!Z(B!4'LN3
MDG-?N-7X`_\`!L.`/^"B_B4#_HFMY_Z5V=?O]7/Q;3A2S;DBK)1BD89#*4\#
M>3N[RW]0HHHKYD]H****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***"0!GT%`!4
M&I:C::59OJ%]/'%#$I:6660*J*!DL2>``!7GW[1/[3/PN_9S\)+XE\>ZJ_VB
M<LFDZ/9X>[U&8#/EQ)D9P#RY(10<LP%?&7CCXX_$G]IS5A<_$Z6.VT$3[K+P
M;9W#/9H,C#7+$#[7(,9^8"-3]U,C<>S"X*KB8\^T>_\`EW(E4478^G_%'[9=
MIXJEDT+]GOPRGB-PY23Q'>W!M]*B(/)1PI>[QZ1#8>AE6N7\3>!?$7C;2&O_
M`(N_$74?$)D!9]*A'V+2U_V1:Q-F1?:=Y>]<]\.3^[C4#`"@!1T`Q7I.L_\`
M(`_X!_2JJ)49I4_^#_7H"7,KL^??B#I.EZ#8C2=%TZ"TM85VPV]M$$1%'8*.
M`*^:?BKUD'^U7T_\5_O2?0_SKY@^*O63_>KZ/+=4KF%;2)\U_%#_`%CU\\?%
M+_5R_C_*OH?XH?ZQZ^>/BE_JY?Q_E7V>#V1XF-_A,^J_^#8C_E(OXD_[)K>?
M^EEG7[_5^`/_``;$?\I%_$G_`&36\_\`2RSK]_J^$XQ_Y'3_`,,?U.GA_P#W
M#YR_,****^6/<"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`$9E1=S'`'>O'_VQ
M_P!K[P'^R1\-F\6Z^POM7O\`=;^'/#\4NV74;D#.,X.R-00SR$85?5BJGT#X
MJ_$KP9\(?AUK7Q,\?ZU%8:1H5A)>:A<R'[L:#.`.K,>`JCEB0!R17X@_'?\`
M:<\9_M<?&^_^,/B^22&&4_9]"TDR933+%6.R$8XW'[\C?Q.QYVA0/9RC*Y9A
M4<Y:0COY^1S5ZWL].IZ-J7Q1\??&_P"(5U\4OBCKIU'6;[Y-ZJ4AM8`Q*V\"
M9/EQ+Z=6.68LQS7K?P[^Y%]17@OP\!;R\#/3I7MG@CQ-H>GWD.D2WRRWSX,6
MFVL;SW4O^Y!$#(__``%37TN,IPIQ2222V78RIW>Y]&_#G[D?T%>DZS_R`/\`
M@']*\S^&OASXU:I`DOASX#>(GCXVW.M^3ID1_P"`W#"<?]^C7I*_"#]I3Q):
M"UU#4O!WAZ+C<B076JR8[\YM5!_[Z%?(UU'VE^9?>=46TCP?XL.H9\MV-?,/
MQ6X,F?7-?H)=?L%IXAD$WC/XY^)YV8DRPZ5IUA;0G/90\$KC_OLGWI\'_!,'
M]E&YP?$VC>(M7D'WI+SQ5=Q!_JMO)&OZ5Z>%S+"8:W,V_1?YV,Y0E45D?C+\
M4`?,DXZ=:^=_BFV$E^4]^@K^C"U_X)A_L(VT@EE_9WTN[8=]1OKNZ_\`1TK9
MJTO_``33_8%`(D_9(\"RYZ^?X?AD_P#0@:]BEQ9@J.T)/[CAKY?4JP:N?CA_
MP;%ND?\`P47\2[VQ_P`6UO.._P#Q^6=?O]N7&<U^>G_!2?\`9I^`7[,.@^$O
M$O[.GPAT#P/J.H7UY!?7WA;38[&:>(1(VQWB"LRYP=I.,BOE"+XT?&'19`^D
M_%?Q+;%.5\C7;A<?D]?-YWF=/-L=[>$7%62U\C;+<'/`X;V<G?5_B?MV2!U-
M&1G']*_&31OVZ/VNO!SA]"^/NOG!SLOKA;I?Q$ZOG\:]&\"?\%EOVJ/"$D</
MC#2O#GB6$'$C7-@UM,P]F@8*#]4/TKR#T#]5:*^)_A3_`,%N?@1XE:*P^+'@
MC6/"\[$"2ZMP+VV4^N4"R`?\`-?5/PG^/7P;^..E'5_A/\2M'UZ)1F1+"\5I
M8O9X\[XS[,`:`.OHH!!Z&B@`HHHH`****`"BBAL`$D\8H`**^:/^"AG_``51
M_9:_X)O>'=/O?C7XANKS6M8C9]&\+:%"L]]=HI(:0JS*L48(QO=@"00,D$#X
M1N_^#NOX0QW3BQ_8S\2RP9_=/-XJMXW(]U$+`?F:]3"9)FN.H^UHTFX]]%^=
MCSZ^:9?A:GLZM1*78_86BOQW'_!W?\*/^C*O$'_A80?_`"/1_P`1=_PHZ?\`
M#%7B#_PL(/\`Y'KK_P!5\]_Y\/[X_P"9S_V]E/\`S^C^/^1^Q%&1G%?CO_Q%
MW?"G_HRGQ#_X6$'_`,CUV'P9_P"#KS]DOQOXIMM!^+OP/\6>"K2XF5#JZ3PZ
ME!`"<;I!'LD"CU56[\5$^&L\A'F=%Z>:?X)E0SS*IR2]LM?7_(_5BBLGP1XV
M\*?$;PGIOCKP/X@M-5TC6+&*\TO4K"<20W5O(H=)48'#*RD$$>M:U>&U)-I[
MGJIIK0,C.*,BOF3_`(*C?\%(-#_X)E_!;2?C1XC^%][XLMM5\11Z4-/LM02V
M9&>&23?O96&!Y9&,9^:OGS_@GK_P<,>!_P#@H)^U+HO[,?AS]FC5_#5SJ]E>
M7"ZK>>(8KE(Q;V[S$%%A4G(0CKQ7H4LJS"O@WBH0]Q7N].F_4XZF88.EB50E
M.TWLK/KL?H]1117GG:%&<45Q'[1OQBB_9]^!OC'XX7>B2ZE!X0\+WNLS:?#*
M$>X6VA>4QAB"%)"XR0<9IQC*<E&*NV)M)79V^117X\VO_!W)\+=0O8;*']B[
MQ`GFRJFX^+H#C)`_Y]_>OV$B9FC5G7!*C(]#79C<MQ^6\OUF'+S;')A<?A,;
M?V$KVW'445\O?\%3?^"EVA_\$Q/A)H/Q;\1?"J\\66^M^(5TM;.RU);5HF,,
MDN\LR,"/W>,8[UAA\/6Q5>-*DKR>R-ZU6G0I.I4=DMV?4-%?GE_P3J_X.%O@
M3^WY\=_^&?[SX67W@'6+VQ:;P\VJZU'<QZI,AS);JRQILD"?,H.=P#`<@`_H
M8KHW"L#]#6F,P>*P%;V6(CRRWL1A<50Q=+VE*7,NXM%%%<IT!117D?[;G[8G
MPP_8:_9UUW]HKXHW@:QT>(+::?#*!-J-V_$-K%G^-V_(`D\`U=.G.M45."NW
MHD3.<*<'.3LEN>N9HK\A?"/_``=D_"_Q=XLTKPC!^QMK]O)J>I06BW!\6PL(
MS)(J!B/(&0-V<9[5^N]N[R0JTHPQ'/%=>-RW'Y;**Q,.6^W](Y<'CL+CH.5&
M?-;<?1F@C(Q_*OE+_@JK_P`%0_#_`/P2Z^'OA;X@^(OA+>^+HO%&LRZ=%;66
MJ):F!TA,N\LZ.&!`QC%<^'P];%5XTJ2O)[(WKUJ6'I.I4=HK=GU;17X[C_@[
MM^%1.!^Q1XA_#QA!_P#(]'_$7?\`"CI_PQ5X@_\`"P@_^1Z]G_5C/?\`GP_O
MC_F>9_;V4_\`/Z/X_P"1^Q%%?CO_`,1=_P`*.G_#%7B#_P`+"#_Y'H_XB[_A
M0/\`FRKQ!_X6$'_R/1_JQGO_`#Y?WQ_S#^W<J_Y_1_'_`"/V(HR,XK\?])_X
M.Z/@I<:E##KG['7BBUM"V)I[7Q-;3N@]0C1(&^FX5^B7[#7[??[._P#P4#^%
MQ^*GP`\6F[AMI!#K&DWT/DWNESD9$4\1)QD9*L"58`D$XKBQF39GE\/:8BFX
MQ[Z-?>F=.%S/`8N7)2J)OMU_$]NHH!!&0<@]#392RQ,R]0IQQ7FK4[QV:*_)
M+XH?\'6GPR^%_P`2_$?PUOOV/-=O9?#VNWFF274?BR%!,T$[Q%POD'`)3.,]
MZQ!_P=W?"D_\V4^(/_"P@_\`D>O=CPSGDXJ4:+:>NZ_S/(>>Y4I-.JE;NF?L
M117X[_\`$7?\*0<']BKQ!_X6$'_R/1_Q%W_"C_HRKQ!_X6,'_P`CU7^K&>_\
M^']\?\Q?V]E/_/Z/X_Y'[$45^.Y_X.[_`(4#_FRKQ!_X6,'_`,CUW7[,7_!S
MU\._VG/VB?!7[/>D?LFZWI%QXR\1VNDPZG/XHAF2V::0('*"$%@,],BHJ<-Y
MW2@YRHM):O5?YE0SO*ZDU&-97?J?J=02`,FD4D@9ZXYKCOVBOBW!\`?@!XW^
M.MWHTFHP^"_"6HZ[-I\4H1KE+2VDG:(,00I81D9((&<UXL8RG)1CN]CU)248
MMOH=E17XZ+_P=V?"E>/^&*_$'7@CQA!_\CT__B+N^%/?]BKQ!_X6,'_R/7N?
MZL9]?^`_OC_F>4\]RG_GZOQ_R/V(HK\=_P#B+O\`A1_T95X@_P#"Q@_^1Z/^
M(N_X49Q_PQ5X@_\`"Q@_^1Z?^K&>_P#/A_?'_,7]O93_`,_H_C_D?L1GG']*
M*_'JS_X.[/@]+?11:C^QIXFAMS(!-+!XHMY'1<\E5:)0QQV)'U'6OT!_8'_X
M*4?LW_\`!1CX>W?CGX`^(;D7&DRQQ:]H&KVZPWVFNX)3S$#$,C;6VNA93M89
MRI`Y,9DN:X"G[2O2:CWT:_!G3ALSP.+GR4JB;_KN?0E'2BH[EY$0&,<EL=*\
ML[R3(HK\H_C]_P`'2OPW^`_QO\8?`^^_9$UW4+GPCXFO='FU"+Q3#&MP]O.\
M1D"&`[0=F<9.*^_OV#_VK]._;A_92\)_M2Z3X-G\/VWBN*ZDATBYNQ.]N(;N
M:V(+JJALF$MP!PPKOQ65YA@J$:]>'+&6S[WV.*AF.#Q-9T:<KR6Z]-SUZBBB
MN`[0HHHH`****`"BBH-1OK;3K&6_N[E(H84+RRR,`J*.223P`!GF@"?.**_)
M#XE?\'9'P+\&>/\`6_"/A']EW6_$FG:9JD]KI^O0^)8K=-0C1RJS+&T#%5;&
M0"2<$5]V_P#!-_\`X*#_``S_`."CG[/$7QW\!Z>VD3Q:E-8:QX>N[Q)9].N$
M((5F4#<'1D=6P`0V.H->EB\GS/!4%6K4W&+Z^IP8;,L#BJKITZB;70^@J***
M\T[PH)`ZT4DA*H2H)('`%#V#6XM%?FM^WE_P<7^!?V%/VIO$G[,?B#]F'6/$
M5SX>6U+:O:>(XK=)A-;QS#"-"Q&/,QU[5]0_\$[/^"DGP#_X*-_"%?B3\*-6
M6RU2T`C\1>$[Z=3>:3-Z.!]^-NJR`;6'H05'H5LJS&AA5B:E.T'L_4X:.8X*
MOB'0A.\UNO0^B**`0PR#D>U%>>=P445Y]^U7\>+?]F']G7QC^T%>>'9-7@\(
M>'[G5)M-AG$3W"Q(6*!R"%)QU(JH0G4J*$5=MV)E*,(N4G9)'H.?\XHK\I_V
M>/\`@Z.^&_[07QW\&?`K3?V1]<TVY\8>)['1H=1F\50R);M<SI")"@@!8`OG
M&>U?JK`S/"K/UQS77C<OQF734<1#E;5UJOT.;"8W#8Z+G0GS):#Z"<45S?Q?
M\?K\*_AAXA^)<NGM=Q^'M"O-3EM$;:TRV\+2E`V"%)"$9[$BN-)RDDMV=3:2
MNSI**_'5/^#NWX5!`S?L5>(/0_\`%8P?_(]._P"(N[X4_P#1E7B#_P`+&#_Y
M'KW?]6,]6]'\8_YGDO/<I3_C+\?\C]B**_'?_B+O^%)''[%7B#_PL8/_`)'H
MA_X.[/A(\X%Q^QCXD2/^(Q^+;=C^1@'\Z/\`5C/O^?#^^/\`F"SW*?\`G]'\
M?\C]B**_,[X1?\'37_!/CQ[J$.F_$7PSXW\$F4A6N]3T>.[MXR3U)M9'?'OL
M_"OO;X"_M*?`S]IWP5#\1_@+\5]$\5Z+-\IO='O5E$3]?+D7[T3@=4<!AZ5Y
MV*RW,<#_`+Q2<5W:T^_8[</CL'B_X,TWV3U^X[NBD#*PRI!'J*AO]0L].MI+
MJ]NHX8XHF>225PJJH!)))X`XZUQ=3JO8G)`Y-&:^0M0_X+"?!GQ'XBO]#_9N
M^"?Q3^,MMI5PT&I:_P##+P3)>:7%*I.8UO)&CBF;VC+9[$UZ/^RK_P`%#/V>
M?VL?$6I?#WPGJ>K>'O&FAP^9KO@'QMHTNDZU8KQ\[6TX!=.1ET+*,KDC(KJG
M@<;3I>TG!I+?R]>J^9SQQ5"<N527]=CW:BD#*PRI!!Z8I:Y3H"BBH-2FCMK1
MKF:0(D8W,Y/W0.2?RI!==3\Q?^"_'[5=Q_;?A_\`8^\+ZGMB:*/7/%RQOC<-
MQ%I`W_`E>8K_`+,1KY1_91_9L^.'[26N'1O@YX#GU1+:39?:I,_DV-F>N)KA
M@55L'.Q0SX_AKV7]EW]C/Q)_P57_`&Q?B!^UE\4;N\L/AQ)XON$MKB(E9M92
M!A##:PMG]W&D$<0DD'()*K\V63];?AM\./!7PE\&V?@#X>>%['1M'TZ,1V.G
M:=;B.*)<=@!R2<DD\DG))ZU]I6S*CDN#AA*"O42O+LF][]V>;2I3Q-5U9;=#
MY._9Z_X)$>!_#-G'J?QZ^(-_XBO0!OTC1I7L;!/4,R'SYO3.]%(_@KZF^'OP
M7^%_PGTT:1\-/`NDZ';X`*:;I\<1?'=F4`N?<DFNHHKY6OC,3B7>I*_Y?<=\
M:<8["*-JA?2EHHKF+"BBB@`HHHH`^*_^"SG_`"(O@;_L+7O_`*)2OSSO^I^E
M?H9_P6<_Y$7P-_V%KW_T2E?GG?\`4_2@#*O.I_W:R;K[Y^M:UYU/^[63=??/
MUH`RKO\`B_SVJ#1?%?B;P7K47B'P?K][I=_;MNAO+"Y:*1#[,I!':IKO^+Z?
MTK)O/O&@#[F_9._X+%_&WP4;?P_\=[!?&&E*`IU!%$6HQ#IG</EEQZ,`3W>O
MT6^!?[2'PB_:*\/C7_A;XJAO`B`W=B_[NYM"?X98C\R_7E3V)K\(_!G5/]X5
M[3\(?%OB?P)X@M?%?@W7[K3-1M6S;WEG*4=<]0<?>4]U.5/<4`?M=17S9^R5
M^W5I_P`4VM?`?Q:6#3?$3A8[2_BPEKJ3=,`'_52G^X20W\)_A'TDC;U#8Q0`
MM%%%`!39N87&<?*>:=2/]P_2FE=AL?S!_P#!PG\2M9^(G_!5;XAV.I:@\UOX
M833]'TU=^5ABCLXI651V_>32$^Y->H_\$SO^#?.'_@H=^RMIO[2LG[4[>%#J
M&IWMG_9`\'_;`GD2F/=YGVJ/.<9^Z,5X%_P6]_Y2L?&G_L:$_P#26"OVI_X-
MG?\`E%3X:_[&C6?_`$J:OU3,L;B<JX:H3PLN5M16R>ZOU\T?GV7X:CC\_KPQ
M"YDN9]>]NGJ?*O\`Q"&VAY/[>3?^&[_^[J/^(0VT_P"C\V_\-V/_`).K]JJ*
M^+7%6??\_O\`R6/^1]/_`*O9/_SZ7WO_`#/Q5/\`P:'6@&/^&\G/T^'?_P!W
M5^8G_!1#]CQ?V#OVL?$7[,:>/CXF_L&&T?\`M@Z=]E\[SK>.;'E;WVXWX^\>
ME?URG)!`]*_-?]OW_@W0\&?MY?M2^(/VG-:_:FU3PW<:]':HVD6WA>.Y2'R8
M$AR)#.A.=F>G&:]G(^+<1'%O^T*ON6[+?I\*N>7FO#E"6&7U.FE._=[?-FY_
MP;*?$[6_B#_P3+T[0M=O7G?PIXJU'2;1I&)*V^8[A$Y[*;AE'H`!7Z&5\V?\
M$O\`_@G9H_\`P31^`M]\"M#^*%UXLAO?$,^JG4KO35M65I(XD\O8KOD#RASG
MO7TG7R>9UJ&(S"K5H_#)MKYGT>7TZM+!TX5?B22?J?EQ_P`'7_\`R8=X0_[*
M9;?^D=S7YR?\&V'_`"EE\%?]@#7/_3=/7Z-_\'7_`/R8=X0_[*9;?^D=S7YR
M?\&V'_*67P5_V`-<_P#3=/7WV4_\D96])GQ^:?\`)34/^W/S/Z8J***_,S[L
M*\2_X*2?\F`?&[_LD^O?^D$]>VUXE_P4D_Y,`^-W_9)]>_\`2">NC"?[W3_Q
M+\S*O_!EZ,_DCT#_`)#EG_U]Q_\`H8K^TA/N#Z5_%OH'_(<L_P#K[C_]#%?V
MD)]P?2ONN/?CP_\`V]_[:?&\'?PZO_;OZBU^5/\`P=F<_L6^`/\`LI2?^D-S
M7ZK5^5/_``=F<?L6^`/^RE)_Z0W-?,<.:YY0_P`7Z,^BSO\`Y%57T9^#/@OQ
M-XP^'OB/3?B/X+U.[TW4='U*.XTS5;1BC6US&0Z,K#HP(SCVK^H__@D+_P`%
M%O#7_!1O]EZS^(LTUM;^,M#$>G^.M(A('D7H7(F1<Y$4P!=?0[EY*&OQ'_X)
M5?L$W?\`P4%_8R_:4^&_A:-&\7>&;GPKKG@S>0HDNT365DMRW\(EC^3/3<$/
M:O)O^":G[<WQ(_X)D_M=6GQ%FL;U=+^U'1_'_AJ8%'GL]^)5*'`$T3KN0G!#
M(5R`QS^@9[@J&>TJM*G;VU%Z=VFD[>C_`#/C<GQ53*94ZD[NE4W\FG:_R_(_
MJ^HKG?A3\3_!/QD^'NB_$WX<:Y#J>A:[IL5[I6H6[@I/!(@96&.G!Y'8@@\B
MN@D<1(7/0=:_)91G"7+)69^C)IJZ"3`4[NA'-?S;_P#!P/\`\%*I?VUOVEU^
M!OPJUQ[GX??#R\DM+)[5]T>KZG_JY[KC[ZJ1Y49YX#L/OU^F/_!PM_P4Q7]C
MO]F\?`[X7ZT8/B)\1[*:UMW@D_>:5IG*3W?'*NV6BC/KO8?<K\CO^"0_[`_B
M7]J?QMXO^/&MZ4X\$_"KPM?ZO?WDL?R7>I)9RO9VJYX8B11*WHL>#]\&ON>%
M\#1PE"69XG1+2/KM=>?1'RF?8NIB:\<!0W>LK=NS_-_(^7/@H#_PN+PF3G_D
M9;#K_P!?"5_97%_JE^E?QJ_!48^,?A/'3_A);#_THCK^RJ+_`%2_2MN/%^]P
M_I+]#'A'^!5_Q+\F.K\C_P#@[C_Y-I^$O_8^77_I$]?KA7Y'_P#!W'_R;1\)
M?^Q\NO\`TB>OG.&?^1[0]7^3/;S[_D4U?3]4?E-_P2[_`&%++_@HI^U/;_LX
M7WQ(F\+1S:%>:C_:L.FBZ8>0$.SRRZ==W7/&*_2@?\&BGAD\C]N"^'L?`\?_
M`,EU\K_\&QK;/^"HU@<9_P"*%U?_`-!BK^D-+E`@&5X'<G_"OI^*\[S3+LS5
M+#SY8\J>R>_J>!D&5Y=C<N]I7A>3;_#T/QD_XA$_#/3_`(;AO?\`PB(__DNE
M_P"(17PRO7]MZ^/L/!$?_P`EU^S?VI/[R_F?\*0W<8ZLOY__`%J^9_UKS[K6
M_P#)8_Y'M?ZOY+_SZ7WO_,_F!_X*T?\`!'/QQ_P2[?PMXAE^*UKXR\-^*Y9[
M>TU"/2C93VUS$JNT4D7F2`AE;*L&_A8$#C/MO_!JE\0O$>@?M[>)_`%G>R?V
M9K_PZN9;VU+'89H+JV:*7']Y0\J@^DAKZ2_X.XO$^A/\&?@]X5_M*(:B_BG4
M;I++>/,,*VR*SXZX#,HSZFOE7_@UJTW4+K_@I#J=];6<CPV?PUU%[F0+Q&&N
M;1!GTRS*!]:^V6,KYCP?4JXK65GK;?6R/FUAJ."XGA3H*T;K3Y']%L8P@&,?
MA2O]P_2DAYCZ=S_.E?[A^E?E4%96/OWL?QV?M9_\G4_$S_LH.L_^ETU?H_\`
ML>?\&RMM^U?^S%X(_:+?]L9M"'C'P_!J8TD>"!<?9O,&=GF?;%W8]<#Z5^<'
M[6?_`"=3\3/^R@ZS_P"ETU?T\_\`!':01?\`!,/X(;N?^+?670_[)K]8XCS+
M'9;E>'GAI<K=D]$^E^J9^=Y!@<+CL?5C7CS):]>Y^>'_`!"'6A.3^WFW/_5.
M_P#[NH_XA#;3_H_-O_#=_P#W=7[2BZCQP*&NT49P:^*?%/$"_P"7O_DL?\CZ
MO_5W)U_RZ7X_YGXM'_@T-M/^C\V_\-W_`/=U=]^RM_P;#1?LN_M+>!?VAX?V
MR3K9\&>)K35QI3>!_LXNC!('\OS/MC;,XQG!K]:T<.NX#CM2UG4XFSRK3<)U
M=&K/2/Z(J&0Y33FI1I*Z\W_F(O3//3H:\9_X*/?\H\_CO_V1OQ/_`.FJYKV>
MO&/^"CW_`"CS^.__`&1OQ/\`^FJYKQ\&K8FFO-?FCTL3_N\_1_D?R,:9:"_U
M"WL3)L\^=8]^,[<MC./QK]JK;_@T=\,W5NERO[;=^N]`VT^"(^,C./\`CZK\
M6O#_`/R';'_K\C_]#%?V?Z/_`,>$?_7-?_017Z=Q=FF/RU4/JT^6_-?1/9KN
MCX+AG+L'CX5/;PYK6MOUOV/QI_XA$_#7_1\%]_X0\?\`\ETG_$(IX8!`/[;]
M_P`G_H2(_P#Y+K]H:*^+_P!:<_\`^?W_`)+'_(^I7#V3K_ETOO?^9_,'_P`%
M9_\`@C%X[_X)?6?ASQH/BQ;>-/"OB2]DLHM132C93V=TJ>8(I(_,D!#(&*L&
MYV,"HP"?1_\`@UT\;^(/#W_!2:?PAI]XRV'B#P'J,>HV^X[7,+PS1OCN5*D#
MV<U]P_\`!V1S^Q-X%(P<?$N+O_TX7-?!'_!LC_RE*T<_]2;K'_HI*^THXROF
M?"%6KB7S2M)=MMCYF>$HX'B>E3H*T6U^)_24#SCVI)>B_P"^*=39>B_[XK\J
MO=7/OG\)_(G_`,%%O^3_`'XU?]E4U[_TOFK^BC_@@!_RB'^#G_7AJO\`Z>+Z
MOYU_^"BW_)_OQJ_[*IKW_I?-7]%'_!`#_E$/\'/^O#5?_3Q?5^E\6_\`(BP_
MK'_TD^'X>_Y'-?\`[>_]*1]C4445^:GW04444`%%%%`!QWK\[?\`@XP_;_;]
ME']CJY^"W@C6?L_C'XHI-I5DT$F)+73``+R?U&Y&\E3US*2/NFOT$\2:SI?A
MW1;G7];OHK6SLH'GN[F=]J0QHI9G8GHH`))]!7\J7_!4S]L_Q!_P41_;DU_X
MH:&ES<:.;U-%\"Z;%EBMC$^R(HO]^9RTQ`&=TN.<5]-PME?]H9A[2:]RG9OU
MW2/"X@QWU/!.,'[\]%^IQW[.?["WQQ_:<^"/Q1^/7PVT<RZ+\*M%BU'6B8F+
M76^3+Q1=BZ0K+,PYPL8&,L*^C_\`@WQ_;['['/[95M\.O&VM?9_`_P`3&@TG
M6#+)^ZL[X,19W1)X`#LT;'^[+DG"BOVU_P""4O[!FB?L0?L(>'_@AK>C6T^M
MZK9OJ7CD/&&%U?W,8$L3<$,J1A(!U!$>>]?SS_\`!5[]B;4OV!OVU_$_P?L;
M:5/#MU/_`&MX,N></IT[,T:ANYC8-$3ZQY[U]?A<VP_$-7$X&I\+7N=]-+^M
M]4?-5LOK9+"CC(:R7Q=M>GW71_6!17Q9_P`$+OV^8OVZ/V*]*O?%6M+<>./!
M:1:'XP$CYEN)(TQ!=MGD^=&`Q/\`?60=J^TZ_,L5AJN#Q$J-16<78^\H5Z>)
MHQJ0=U)7"BBBN?H:O8_F"_X.&"W_``]E^):@\&+2O_3=;U\\_LF_M7?'/]B'
MXW:5\<_@EX@FTS5K(CSK6;<;;4+5P"UO/'QYD3K^7#`@@$?0W_!POC_A[-\2
MP3QY.E?^FZWKW_P?_P`$A[W]OG_@B_\`"K]I7X#:9$/BIX7LM8LY=/X'_"1V
M$.KWJK!DD`3H%/ED\$?(?X2/V.GC,)A<DPL<4KPFHQ\M8]?+0_,ZF'Q&(S?$
M.@[3@W)6ZV9^M/\`P3/_`."E?P8_X*0?!.W\>_#ZYCL/$&GHD7BSPK-.#<:9
M<$'G!P7A<@E)`,$9!PP('TK7\@?[,_[2W[07[`'[1%M\4OA?>W6A>)_#U\]O
MJVDW\3JMPBL!-9W4)()4[=K*>5(!!#`&OZ8?^"9'_!3CX(?\%(_@RGC/P#(-
M,\2Z;MB\5>$KF=6GTZ8]&!'^LA?G9(!S@@@$$5\)Q#P]/+)^WH^]1?5?9OW\
MNS/K\FSF&/A[.II46_GZ?JCZ;KYX_P""L_\`RC6^-O\`V3C4_P#T2:^AZ^>/
M^"L__*-;XV_]DXU/_P!$FO!P/^_4O\4?S1ZV+_W6?HS^9[_@FO\`\I"O@A_V
M5;0?_2^&OZY;?_4K]*_D:_X)K_\`*0KX(?\`95M!_P#2^&OZY;?_`%*_2OLN
M//\`?*'^%_F?+\'?[G4_Q?H/KSC]K_\`Y-6^)?\`V3S6O_2*6O1Z\X_:_P#^
M35OB7_V3S6O_`$BEKXG#_P`>/JOS/K:G\-G\>]I#]HN8[??M\Q@I(&<9/IWK
M]F?#W_!I+;^(-!LM<D_;J>$WMG%/Y)^'P;9O4-MS]N&<9QFOQHTW_C_@_P"N
MJ_\`H5?V:_#W_D0=$_[!%M_Z*6OU#C#-LPRSV7U:?+S7OHGM;NGW/S_AK+<%
MCE5=>'-:UM_/L?C8?^#0ZT52W_#>3<=O^%=__=U97B'_`(-%?%4=JT_A+]N/
M3YI=HV0ZCX!>-2?0O'>N1^"FOW`HKXR/%F?Q=_;?A'_(^H?#N3O_`)=?B_\`
M,_F4_:Y_X-Z_^"A'[*V@7GCFP\+:9\0-`L4+W-]X+N'FN(8QU=[5T67`&22@
M<``DXQ7SS^Q5^W#\?/V"/C39_&'X'^)IK66&55UG0IY&-GJUN#\T%P@^\",X
M;[R'!'2OZ[IX?.&..F#GN*_GQ_X.:_V!/!W[.?Q\T']J/X6Z%%IFC?$J2XBU
MZPM(@L,.KPA6:5`,!?.C;>1@9=';^(X^GR+B.6<5?J./BI.2:3MH_*W?S/`S
M7(XY7#ZY@Y-<KU5]O0_;7]B7]K[X;?MO?LY^'/VAOAA/_H.LVQ%Y9.^9=/O$
M.V:VD_VD?/U4JPX85X7_`,%R?%/BJP_92\/?"GPUXBN-(@^*?Q1T'P5KNIVK
M[)+?3;V60W&UOX2R1>7GTD([U^?/_!IU^T_J>A?&#Q[^R-K&HNVFZ]I:^(]$
MMW?Y8KN!D@N-H]9(GB)_Z]Q7ZY_MU_LC>&_VV_V<-=^`_B'69-*FO4CNM%UN
MW0M+I>HP.);:Y09&2D@&0""5)&1FOE,9@X9+GWLI_!%IKT>S^7Z'T>$Q4\QR
MCVD/B::^:W^_]3\[/VV$^`'[,O[<MY\+O%W@WXU)\*?`GP!TR[L-#^">KWEK
M#HQ2^N(VO+I;>YA54*#!E?.6P6R>:P?'GA/XU?"?]@[X7_\`!0'X@76L6WC_
M`,%?&FUG^&VJZ_J<=WK5UX+U*]6&#3=0N8R?M&^WFW'DX'3;DBO8/`GC7X^_
M`;XZ:S\2OV[_`-ASXI>-_%]_\/(/`VI>(/A/H]MKOAWQ#817#RBY,)>.:VFE
MWD/'(-O)P`#@5OV5/V$OV@_V@M5\#>`?B=X%\4?#_P#9R^%OBR3Q+X-\$>/]
M0@N/$&LW2R/)96TZ0`BWL;9G)2*1GD(`4Y&-GI^VIT:474DK0Y;N]^:R::BK
M[M[Z:IZVL<;INHY<B>NRM9QU6KTZ>OWGZ<V^XPH<\;?2I*9`ABB6+^Z,4^OC
M%:VA]&%87Q,\.:SXO^'NN>%O#NJK8W^HZ1<VUE>NA86\TD3(DA`()"LP.!V%
M;M1W=W:V%K)?7URD,,,9>665PJHH&2Q)X``YS5)M.Z$U=6.0_9\^"7@_]G7X
M+>&?@GX'L$ATWPUI,5E;D(`TI4?/*WJ[N6=CW9R>]=G21O'(@DB<,K#*LIR"
M*6B4I3DY2W8)**L@HHHI#"BBB@`HHHH`****`/CG_@L#X8\3>)_!/@J'PUX<
MO]1>'5;LRK8VCS%`8D`)"`X_&OS^U3X<?$2`MY_@#7$P.=^D3#'URO%?N,R*
MWWAF@HAZJ..F!0!^#&K>'/$5DK/>:!>P@`@F6T=<?F*YZ^BEB;][&RY/`9:_
MH$FL;.Y4I<6L<@/4.@/\ZR-7^&/PV\0(8]>^'NAWRGJ+S289<_\`?2F@#^?N
M\X+`GMZ^U9%X.2?7I7[Q>*?V'?V0O&".-<_9S\)EGR6>UTE+=B?]Z$*:\F\<
M_P#!&O\`8E\7[Y-)\*:UX?D?^/2=<F<`^NVX,H'TH`_);P9U3_>%>L>#/X?K
M7UGXL_X(7_V07N/A-\<VDVG,=KX@TX#/MYL1_P#9*\R\4_L"?M2_!S==:S\-
M9=5L8_O7_AZ47B<=3Y:_O@/<H![T`4?"<<<BA)4RN>1_GO7VU^R+^TY?ZV+7
MX5_$O46EOBH31-7E)S>`#_4RD_\`+4`9#?QC/\0.[XF\)YBG>VE4I+$VV6-P
M0R'T(/(/L:]4\)P)=1JHF=&7!CE@D*O$PP0R,.58$`@CD$`T`?HB&!)`/2EK
MSS]G3XLS?$GP<UGX@F4:YI)2'4U`VB;()2X5>RR`$X'`974?=KT.@`I'^X?I
M2TC_`'#]*:W$]C^5;_@M[_RE8^-/_8TI_P"DL%?M5_P;.?\`**GPU_V-.L_^
ME35^*O\`P6]_Y2L?&G_L:4_])8*_:K_@V<_Y14^&O^QIUG_TJ:OTKB+_`));
M#?\`;G_I+/ALC_Y*/$>DO_2D?H!1117YFMC[H*,#.['/K2-NVG;UQQ7RO^T-
M_P`%F_\`@G?^R?\`%S4_@9^T!^T"^A>)])2%[[33X1U:Z\H21B1/WEM:R1G*
MLIX8]:VHT*^)GRTH.3WT5W^!G5KTJ$>:I)17F['U3@=<45Y3^R1^V7^S[^V_
M\/[CXK_LU>/V\1^'[74I=/FOFTFZL]MP@1F39<Q1N<*Z\XP<\5ZM4U*=2C4<
M*B::W3T*A.%1*47==S\N/^#K_P#Y,.\(?]E,MO\`TCN:_.3_`(-L/^4LO@K_
M`+`&N?\`INGK]&_^#K__`),.\(?]E,MO_2.YK\Y/^#;#_E++X*_[`&N?^FZ>
MOTG*?^2,K>DSX;-/^2FH?]N?F?TQ4445^9GW85XE_P`%)/\`DP#XW?\`9)]>
M_P#2">O;:\2_X*2?\F`?&[_LD^O?^D$]=&$_WNG_`(E^9E7_`(,O1G\D>@?\
MARS_`.ON/_T,5_:0GW!]*_BWT#_D.6?_`%]Q_P#H8K^TA/N#Z5]UQ[\>'_[>
M_P#;3XW@[^'5_P"W?U%K\J?^#LW_`),L\`?]E*3_`-(;FOU6K\J?^#LW_DRS
MP!_V4I/_`$AN:^8X<_Y'=#_%^C/HL[_Y%=7T9Y'_`,&@RJ]Q^T$'4$'_`(1,
M$'_N,UC_`/!RM_P2JF\):M+_`,%"?@=X:5=.U*=8_B5IUE%_J+ECB/4L+_"Y
MPDI_OE'YWL1L_P#!H)_Q\_M`_7PG_P"YFOV6^(O@7PO\3/!FI?#_`,;Z#;ZI
MH^LV,MGJFGW46^.X@D4JZ,/0@FO8S3,JV5<5U*\-M+KNN6.AY>68&EF'#<*,
M_.S[.[U/P]_X-I?^"I:_#3QI'^P%\<O$NW0M>NI)?A[J%W-\EC?L=SV.3T28
MY9/23*C_`%@Q^T?[1'[07PU_9G^"7B3X[_%3619:#X9TN2]O9B0&?:N5B0'K
M([;44=V8"OYD?^"JO_!/SQ]_P3&_:WG\,:)<7R^&-0NCJOP\\1(S*YMPX98O
M,'W9X'PIY!.%?@,*Z;_@H'_P6;^.?[>W[,GP[_9U\6PR6`\/VGF>.;V.4!?$
M6HQLR03,HQA%C"N5/'FR,>BK7J9AP]1SG%TL;A'^[J:S\O/U>WDSBP>=5,LP
MU3#8I>_#X?/R^6_H><_%CQY^T;_P5\_;Z?4],TV2^\3^/]<2QT#2O-8PZ79`
MXBBS_!%#'EW;'9VZDU_1!\.?V+_AU^P9_P`$T?$_[._P\MHY(],^'FKR:KJO
ME!9-4OGLI#/<OWRS=`?NJJJ.%%?*_P#P;>_\$OI/V=OA"/VS/C!X9$7C/QS9
MA?#EM<Q8DTG1VY#8/*R3\,>A$:QC^)A7Z'_M7?\`)LGQ$_[$/6/_`$CDKR>(
M<UA7Q4,%AM*5-VTZM?Y;'I9-ELZ%*6*K:U*FOHGT/Y%/@K_R6/PG_P!C+8_^
ME"5_95%_JE^E?QJ?!3_DL?A+_L9;#_TI2O[*XO\`5+]*]#C[^/0])?H<'"'\
M"M_B7Y,=7Y'_`/!W'_R;1\)?^Q\NO_2)Z_7"OR/_`.#N/_DVGX2_]CY=?^D3
MU\WPS_R/:'J_R9[F??\`(IJ^GZH_#3P/X_\`'GPVUT>)?AOXVU?P_J2Q-&NH
M:+J4MK.$;&Y=\3*V#QD9YQ78?\-D_M>*?^3I_B-Q_P!3M?\`_P`=KZV_X-J/
M#V@>*O\`@IQ8Z5XFT.SU&U;P1J[&VOK998RP$6#M8$9&:_HLB^"?P;,:D_"?
MPV25&?\`B1P?_$5][GO$5#*L?[&5!3T3OIL^FJ?8^0RC):^/P:JTZSBKM6UZ
M>C1_([_PV5^UYG/_``U/\1O_``M[_P#^.T?\-D_M>L>/VIOB-[`>-[__`..U
M_7)_PI+X-?\`1)O#7_@C@_\`B*/^%)?!K&/^%3>&O_!';_\`Q%>-_KKA?^@1
M?>O_`)$]/_5C&?\`00_Q_P`S^/?5_&_B;XJ^,K35/C/\3]<U#S)%CNM9U2XE
MU&XABSR0)9`S`9)QN%?T0?\`!O?^RA^P_P#!W]GZ^^+_`.RY\84^(FN^)0EO
MXJ\27%E]EGLFCPXL?LS9>W52=Q#$ESA@2-N/G'_@ZG_9'^!G@7X0?#[]H[X?
M?#32="U^?Q5)HFKWFCV26_V^&2V>:/S0@`D9#`=K$$@,PSC%?.7_``:Y_&OQ
M9X'_`."A5Y\([#5IAHWC?P=>I?66<QM<6VV>&;'0.JK*H/I(1Z5Z&9UO[;X9
MEB:%Z:5VX]&ET_5?B<N!A_9.>K#U;3<K6EK=7]?Z_(_HJ``&`,?2D?[A^E-@
M=GC#.>2,TY_N'Z5^7+<^\>Q_'9^UG_R=3\3/^R@ZS_Z735;\+?ME?M@>!_#U
MGX1\%_M4_$?2-*TZ!8;#2]+\;W]O;VT0Z)'''*%11V``%5/VL_\`DZCXF?\`
M90-9_P#2Z:OZ3?\`@D9\`/@1XE_X)K_!?7/$?P6\)W][=>`K*2YN[WP[;2RS
M.5Y9F9"6/N:_9,VS6CE.74:E6GSJ22MIVWU/S#+,NK9CC*D:=3D:UZZZ^31_
M.9_PWI^W-_T>9\5?_#@ZE_\`'JTO!O[=O[<5SXNTJVG_`&Q_BFZ2:E`K(_Q!
MU$A@9%&#F:OZL/\`AF/]FW_HWWP3_P"$K:?_`!NA?V9?V<$8/'\`/!2LI!5E
M\+6@(/J"(^*^;EQC@'%KZHOO7^1]`N&<6I:XA_C_`)G5^'G:31X'8DDQ*<D]
M?E%7:;##%;QB*%`JCH!3J^`;N[GV`5XQ_P`%'O\`E'G\=_\`LC?B?_TU7->S
MUXQ_P4>_Y1Y_'?\`[(WXG_\`35<UOA?]ZI_XE^9AB?\`=I^C_(_D8TZ[%A?V
M]\4W>3,LFW.,X;./TK]HK3_@[CL;2V2W/[%5RQ50-W_";JO08_Y]3Z5^+^E6
ML5]J=M93DA)IU1RO4`M@XK]X;+_@TQ_9*N[1)V_:9^(H+*"0(+'`R`<?ZBOU
MKB&>0QC2_M%-O7EM?Y[/T/SG(XYQ*,W@6DKJ][>=M_F<'_Q%VV/_`$9-<_\`
MA<K_`/(E'_$7=8@\_L2W/X>.5_\`D2N6_;V_X-=X?@K\`-0^*7[(/Q.\2^,O
M$&B9N;_PSKD5N'O+-5)?[,88U+3+PP0YW@$#YL`_DOX'MO!5IX]T^T^+5IK"
M:%'J"QZ['H[1QWT4.[:YC$JE?,7DA6')&.,YKS\#E/">9474P\+VW5Y7^ZYV
MXO,N(L#65.M-*^SM&WWV/L#_`(*R_P#!:/X@_P#!4'1_#?@23X46O@[PSX<O
MI+^*P356O9[N[9/+$CR&-``J%@%`_B))/`'I7_!K=\.?$GB?_@HM>^/=/L96
MTSPQX&OFU&Z5#M1[AHXHD)Z`M\Y&>HC;TKZ4_9=_X-P_^":G[4OPRT7XZ_"'
M]KSXA>)?#&JQ"2)[.6PB=7!&^&4?9RT4B_=92`0?P-?IA^Q/^P+^S)^P/\-I
MOAM^SIX#_LV"]G6;5M2NKAI[S4I57`>:5N6QDX481<G"C)KS\SSW*,+E-3+\
M%%IM-6::M?>]];G=@,HS&OF,,;BI)VUTZVVVTL>U"FR]%_WQ3@`.E-EZ+_OB
MOSS6VI]B_A/Y$_\`@HM_R?[\:O\`LJFO?^E\U?T4?\$`/^40_P`'/^O#5?\`
MT\7U?SK_`/!1;_D_WXU?]E4U[_TOFK^BC_@@!_RB'^#G_7AJO_IXOJ_2^+?^
M1%A_6/\`Z2?#</?\CFO_`-O?^E(^QJ***_-3[H****`"@G%%8_COQEH/P_\`
M"NH>-/%.K16.F:58S7>H7D[`)##&A=W8GL`":+-M)=T%TM6?F[_P<L?M\']G
MK]E./]EWP/K?E>*?BAO@O3%*?,L]&C;_`$A_5?-;$`]5,WI7Y\_\&WW["#?M
M2_MF)\=O&6D>=X3^%9CU,B:/]W<ZNQ8V<0/<QLIG/IY2#^*OF3_@I/\`MG>(
M?V]/VPO%O[06IW$XTNZO39^%;&7C['I4)*VZ8'`9E_>/ZO(YKZ<_X)L_\%Z]
M._X)O_LX6OP%\#?LA6&LW#ZE<:AKGB"X\5-!+J-U(<!V06[;0L:QQJ,GA,]2
M:_5:>4XW+N&_JV&A>K4^+RO_`)+3\3\\GF6%Q6>>UQ$OW<-OEMM?KJ?T=PQ"
M.'RR@QSQ7YS?\')'[!G_``U#^R"GQW\"Z&LOB_X5B;45,,7[R[TEP/M</'+%
M-J3*.WEOC[QKY@_XB\/&/_1DVE_^%K)_\BU7U/\`X.V_$.LV,VF:I^PWI%Q;
MW$313PR^,Y"LB,,,I'V7D$'&*^9P'#_$6`QD,13I:Q=]UKW6_8][&9WD>,P\
MJ,ZNDO*7^1\8?\$2OV^;G]@_]M71M?\`$NKR0^"?%X31?&,;.?+BAD<>3=D>
ML,I5B>NQI`/O5_499WUM>0Q2V\RR+)$'1T;(8$9!![U_&7\0-<\-^(_'>L^(
M?!?A;^PM*O\`5)KC3-&%R9OL$#R%D@$A`WA`0H)`)VYK^B__`(-V?^"@,?[7
M/['UO\)?'6N^?XV^&$<>E:CYSYDO-/QBSN?4X1?)8\G=#D_?%>OQKECG".80
M793_`$?Z/Y'G\+Y@H.6#D]-7']5^OWGZ&44B,'7<K9![BEK\YZ'VCV/Y@O\`
M@X9_Y2S?$O\`ZY:5_P"FZWK]F?\`@W/C1_\`@D7\,-Z`XN=>ZC_J-WU?C+_P
M<,_\I9OB7_UQTK_TW6]?LY_P;F_\HBOAC_U\Z[_Z>[ZOT/B&_P#JIA/^W?\`
MTEGQ.4?\E)B/^WOS1Y5_P7$_X(>:1^V'HNH_M/?LR:!::?\`%*PM_,U'2X`(
MHO%$2+]UNRW8`PC_`,8`1CPK#\-?V=OVB?VAOV!_VA+7XH?"W5+_`,->+?#M
M\T&H:=>0O&)55L2V=U"V"T9*D,C#@@$8(!K^P!T5UVL./K7YJ_\`!;S_`((@
M:#^VMHEW^T;^S9H5MIOQ6TRTW7=HA$4/B>%!Q'(3PMR!D)(<;N%<XVE>#AWB
M&%*/U+'>]3:LF^GD_+\COSG)IU)_6\'I46K2Z^:\SZ._X)D_\%//@G_P4@^"
MJ^./!ET--\4:8D<?BSPE<2@SZ=,PX9?^>D#8.R0`9Z'#`BM;_@K/_P`HUOC;
M_P!DXU/_`-$FOY@_@#\?_P!HO]@W]H*#XC_#'5=1\*^+_#E\\&HZ?=PM&'"/
MB6SNH6^^A(PR,.",C!`(_=W6O^"FGPI_X*;?\$=OC1XL\'21:7XNTKX::A'X
MP\(32YEL)OL[9DC)YD@<@E)!V&&PP(IYGP]++<?2Q%#6E*47WY=5IZ=F/+LZ
M68X2=&KI42>G>R_/R/P]_P"":_\`RD*^"'_95M!_]+X:_KEM_P#4K]*_D;_X
M)K\?\%"O@A_V5;0?_2^&OZY+?_4K]*WX\_WRA_A?YG/P?_N=3_%^@^O./VO_
M`/DU;XE_]D\UK_TBEKT>O./VO_\`DU;XE_\`9/-:_P#2*6OB</\`QX^J_,^L
MJ?PV?Q\Z;_Q_P?\`75?_`$*O[-?A[_R(.A_]@BV_]%+7\96F_P#'_!_UU7_T
M*O[-?A[_`,B#H?\`V"+;_P!%+7Z!Q_\`\N/67_MI\;P=\-;U7ZFQ1117YR?:
MA7Y@?\'5NC:=>_\`!/WP_JEQM$]E\2[)K?=@DE[6[5L?A7Z?U^.?_!VA\>=#
MLOA5\-/V:[._CDU34?$%QXAOH$<;HK:")[>,L.H#R3/@]S"WH:]SANG.IGM!
M177]#RL\G"GE-5R[6^;/AC_@W3UB]TC_`(*T_#B*T8A;RUU>"=>S(VFW)/ZJ
MI[\BOZ<R`>HK^;W_`(-A_A?J'CC_`(*<6'C:&U9K7P=X0U._N)@I*J\T8M$4
M^Y$[$?[M?TA#D9KT^-91EFZ[J*_-GG\*1G'+&WUD_P!!@MX`<B%.>ORBG+'&
MARJ`'V%+17R!]*M`HHHH`*H^)=(M_$'AZ^T"[0-%?6DEO(",_*ZE3^AJ]0<G
MH:`/'/V5?BQ)?>';/X2>,;EEUO2+<P6LLYYOH8248`GK)$5*..I"A^C''L>0
M.2:^4OVB_",G@WXHWJ1/)##J,@U?1YX&*-!-D";RV'*NLO[S/_3<=@16Q\+_
M`-MB3P\5\/?&RU>6)3MB\1V$&3CTGA4<''5X\@GG:E`'TK16;X6\7^&/&^E1
MZ[X0U^SU*RE&8KJRN5E1_H5)_'TK2H`****`"BBB@`HHHH`****`"BBB@`HH
MHH`*1E5QAAD4M%`'%_$W]GSX0_%J%CXV\%VT]R%Q'J$`\FYC]UE3#?@21QR#
MTKP'QY^Q_P"-OAB\FM>!+F;Q)I2_,]L8P+^!?]U`%G`'9`K^BL>:^LJ",C%`
M'R9\&?&47A'Q?IGC&RN@UC*XL=69>@@D<+O8=C%*`3G[JF4<9-?68Z=,>U>/
M?'[X&6M]:7OCOPC8M]LDA;^V].MUP-1B*[6=1VG4'((^^!M.?E*]O\%/%Y\=
M_"[0O%$ETL\MSIJ?:95/#S*-DA'_``-6H`ZJFR'$;$D#"GD]J=22)O1D/<$4
M!IU/Y7O^"YNG7&F?\%7?C-#<CF3Q#;S(?59+&W=3^3?I7ZW?\&Z/[1/P'^''
M_!,7P[X9\??&GPCHFHQ^)=7=['5_$=M;3*K73%24D<,`1R.*\:_X."_^",'[
M07Q[^.B_MC_LI^$_^$GDU32H+7Q;X:LV1+Q9X%\N.YA5B/.#1!59%^8&,$!M
MW'Y2:M_P3\_;KT&].G:K^QY\2X+A/O1R>";X$?\`D*OU6,<!G^04:+K*#BHW
MVNFE9Z-H_/7/&9/G%2M&DY*5[>:;OTN?U5#]L;]E(CG]IGX>_P#A967_`,<H
M_P"&Q?V4O^CF?A[_`.%E9?\`QROY2_\`AA/]MD_\VC_$C_PB[[_XU1_PPE^V
MS_T:/\2/_"+OO_C5>;_J;EM_][7W+_,[_P#6?'?]`S^]_P"1_5FW[8W[*?;]
MICX>G_N<K+_XY7\X7_!?7QGX4\??\%1?'_BCP/XHT_6--N+32Q!?Z5>I<0R;
M;"`'#H2IP<C@UX3_`,,)_MM=!^R/\2/_``B[[_XU7=_!?_@D5_P4?^.OB6U\
M.^$_V2/&-@MS*J-JGB32)--LX%)P7>:X"C`ZD+D^@->IE&3Y=D-:6(6)4M+=
M%OKW[GGYEF>.S:@J/L&M;]7^A^R7_!JQ97=M_P`$Z-8NIX=L=Q\2-0,+'^(+
M;V@)^F<C\*_3$^U>!?\`!-#]CBP_8-_9`\)_LVP:G%?WNDVLD^N:C`I"7=_,
MYEGD4'G9N;:N>=J+7OM?G&;XF.+S2M6ALY.Q]OE]&5#!4Z<MTD?F#_P=9:5=
MWW[`/AO48DS#9?$FS,Q`/&^TNE'TYK\Q_P#@WE\;>$/AS_P5(\'>*?'GBK3=
M&TR'0]:6:_U6^CMX4+:?,J@O(0H))P.>M?OO_P`%,_V)[#]OO]CKQ=^SK)JT
M.GZEJ$$=WX?U&XBW);:A;L)("V.0C$%&(Y"R-CTK^;GXR_\`!)#_`(*-?`WQ
M#=:!XM_9'\97BVKE1J?A_1Y-1LYAD@,DUL'7!ZX.&]0*^WX8Q&$Q60U<#5J*
M,GS+5])=?,^3SZABJ&:T\9"#E%)?>OR/Z>_^&Q?V4O\`HYGX>_\`A967_P`<
MH_X;%_92_P"CF?A[_P"%E9?_`!ROY2_^&$OVV?\`HT?XD?\`A%WW_P`:H_X8
M2_;9_P"C1_B1_P"$7??_`!JL_P#4W+?^@M?<O\S7_6;'?]`S^]_Y']6G_#8O
M[*7_`$<S\/?_``LK+_XY7CG_``4*_:I_9I\1_L*?&30]`_:&\#WM[>?##7(+
M6TL_%5I+)-(UC,%1563+,2<`#DG%?S7?\,)?ML_]&C_$C_PB[[_XU4EM^P3^
MV]=2K!!^R%\2I'8X55\%7Q)_\A5=+A#+J56,_K:T:>RZ?,BIQ+CIP<?J[5_7
M_(\Z\$Z9-K'C#2-)M?FEN]3@AC4#^)I%`_4U_9[&28U)]*_GC_X)&_\`!"/]
MK?QW^TMX4^-'[3OPDU#P1X'\)ZQ!JT]KXDA\B\U:6!Q)%;QV[?.BEU4N[A0%
M!`R3Q_0ZGW1QVKSN-<?AL9BJ=.C)2Y4[M=W;333H=G"N#K8;#U)5(VYFK7[*
MXM?E3_P=F_\`)EG@#_LI2?\`I#<U^JU?F5_P=!_"/XK?&3]D;P/X>^$OPVUS
MQ-?6WQ!2XGM-!TN6[ECB^Q7"[V2)6(7)`R>,FO#X>E&.=4')VU_1GKYS&4\L
MJJ*N[,\#_P"#03_CY_:!^OA/_P!S-?MC7X[_`/!JM\#/C;\$;GXZ#XP?"#Q+
MX7_M,>&#IW_"0:+/9_:?*_M;S-GFJN[;YB9QTW#UK]B*VXGG&>>5G%W6G_I*
M,.'H3IY13C)6:O\`FSYL_P""I'_!/CP)_P`%$_V6-8^#VNB*U\0VNZ^\&ZXZ
M#=I^H*#MR0,^5(,QR#NK$]0*_&7_`()$_P#!$'XX_&#]M!O^&PO@KKWAWP3\
M.[\7&MPZWI<D$.NW4<A$5I"[J%GA9D+.R94QC&?G!K^BW`SFD`QTK+`Y_C\!
M@IX:F]);/K&^]O7_`()MBLHPF,Q<*]1.\?N?K_7D16-C;:=;)9VD:I%&`L:*
MH`50,``#H`!BN$_:O_Y-E^(G_8AZQ_Z1R5Z#7!?M166H:I^SIX\TG2;&6ZNK
MOP5JL-M;P(6>61K20*J@<DDX``ZDUY-&RK1;[K\ST9_`S^0_X*?\EC\)?]C+
M8?\`I2E?V5Q?ZI?I7\DWP?\`V'OVS;#XL^%[Z_\`V4?B+###XBL7EFE\&WJJ
MBBX0EB3'@`#))]J_K8@;="I*D''0]17W/'5:E6K4'"2>DMGZ'R?"E&K2HUE.
M+7O+?YCZ_(__`(.X_P#DVCX2_P#8^77_`*1/7ZX5^6G_``=+_!OXM_&?]GKX
M7Z/\(_ACK_B>ZLO&ES/=V^@:1-=O#&;1E#,L2L5&>,GBOG>')PAG=%R=E=[^
MC/:SR,IY5545=V_5'YY?\&V'BOPOX+_X*:6&M^,/$NGZ39CP3JR&[U*]2"(,
M5BPN]R!DXZ9K^B2+]HO]GP1J/^%[>#<[1_S-%I_\<K^34?L)_ML`\_LC?$@_
M]R7??_&J/^&$OVV?^C1_B1_X1=]_\:K[O.<BP6<8OV[Q*CHE:RZ?,^0RO-\9
MEF%]@J#EK>^JW^3/ZS/^&C/V>^G_``O;P;_X5%I_\<I)/VC?V?51F'QU\&Y`
M)Q_PD]I_\<K^33_AA+]MG_HT?XD?^$7??_&J/^&$OVV>W[(_Q(_\(N^_^-5Y
M*X,P+?\`O:^Y?_)'H_ZS8[_H&?WO_(_57_@Z9_;,^!/Q+^$G@']F_P"&7Q2T
M3Q#KEIXKEUK6(-"U**Z6QACMI(8Q*T;$([F9L*3G"$D`8S\F_P#!M5:74_\`
MP56\,7,$9*VWAG6))3_=4VI0'\V4?C7@7P[_`."6G_!13XIZI%I/A#]C3X@L
M\KA?/O\`PW/9P)GNTMPJ(H^K"OVP_P""$G_!&#Q3_P`$_EU;X]?M"WUC-\1/
M$6E"P@TJP<30Z)9,Z2O&9`,/.[(FXK\JA,`MDFO1QM7*\BX?J8*%93E)-*S5
MVWY:VM^AQX:GC<XSF.)E3Y(JU_EZVZGZ2VX'E`CICCZ4Y_N'Z4D48BC6,'.!
MUHF;9"[XZ*37Y<KW/OF?QV_M9_\`)U/Q,_[*#K/_`*735_2C_P`$BOCG\%/#
MW_!-;X+:+KWQA\+6-Y;>`;*.YM+SQ!;12Q,%.59&<%3[$5_/]^U!^Q+^V-K7
M[2WQ#UC1_P!E?XA75K=^.=7GMKB#P?>.DL;WLS*ZL(R&4@@@CJ#7"_\`#"?[
M;/?]D?XD?^$7??\`QJOV#,\OP>=9?1I2KJ'+9]'TMW1^:Y?BL7E6+J35%ROI
MU77T/ZS/^&C/V>ST^._@W_PJ+3_XY1_PT7^SY_T7;P;_`.%1:?\`QROY,S^P
MG^VR3G_AD?XD?^$7??\`QJC_`(82_;9_Z-'^)'_A%WW_`,:KY[_4W`_]!:^Y
M?_)'L?ZSX[_H&?WO_(_K,/[1?[/@Z_';P;_X5%I_\<J6R^/WP)U.]ATW3?C5
MX2N+BXD6."W@\26KO(['`55$F222``.M?R7?\,)?ML_]&C_$C_PB[[_XU7IG
M[%_[%O[8'AO]KSX7>(/$'[+?Q`LK&Q^(.CW%Y=W7A"\CCAB2]B9G=FC`50`2
M2>!6=7@_!4Z4I+%IV3>R_P#DC2EQ)C:E6,7AFKM+K_D?U8@Y/\J\9_X*/?\`
M*//X[_\`9&_$_P#Z:KFO9DY4'CIVKR+_`(*!Z+K'B7]@[XU>&_#NE7-_J&H_
M"?Q%:V%E9P-+-<32:;<(D:(O+,S$``<DFOB\*TL3!^:_-'U.)3>'FO)_D?R*
M>'_^0[8_]?<?_H8K^S_1_P#D'Q#_`*9K_P"@BOY%M#_85_;5AUNR>7]DSXC*
MJW<9=F\&7H"C<#DDQ<5_7/HK,VGQ[D*GRUR#]!7W''-:C56'4))_%MYM'R?"
M5*K3IU>>+5W'?RN6)K6.<8<GWP>M?C!_P<`?\$2?[8&L?MT_LC>#6%VFZZ^(
M7A+3K?/V@#)?4;:-1]_',J`<C,@Y#9_:.HKNU2\MVMY0I5QA@RY!'H17Q^6Y
MEB,JQ*K4?FNZ[,^FQV!H9A0=*KMT[KS1_*U_P2T_X*F?&/\`X)H?&1=9T-IM
M9\#ZQ<(OB_PA+*1'<H./M$.>([A!G#=&'RMD8Q_39^S3^TM\'_VM/@YI/QT^
M!_B^WUG0-8B#03PG#PR`#?#*AYCE0G#(>0?P-?C'_P`%U_\`@A3XB\$^,;K]
MJW]B7X?7>IZ-K-WGQ5X'T*Q:26PNI#S<VL4>2T+DC?&HRC'</E/R_/O_``2\
M^*W_``4\_P"":WQ@7Q1X9_9*^)VL^#=5F1?%_A"7PE?+'>Q#_EK$3$1%<*"=
MKXY^ZP(/'V^:X/+^(L(L=AI*-3JFTK^3\^SZGRN7XC'9-B_JE>+E#HU=VOU7
ME^1_2X.>:;+T7_?%<W\'_BIH7QI^'>E?$GPYIFIV5IJMFD\=EK.GR6EW;D]8
MIH9`&C=2""I[C@D<UT-U)Y:J<9^;N<5^<N+B^5[H^UOS*Z/Y%_\`@HJ,_M_?
M&H#_`**IKW_I?-7[V_\`!"[]I?\`9]\!?\$J/A)X4\:_'/P;I&IVMEJ8NM.U
M3Q-:P3P[M6O&&Y'<,N00>1T(K\7/V^/V,?VO_%/[<'Q>\3>&_P!ESQ_?:?J'
MQ)UJXL;VT\(WDL4\3WLK(Z.L9#*0001U%>2_\,*_MM;=O_#(_P`2/_"+OO\`
MXU7[!C\%@LYRRA2G64>5)]'TMW1^;87%8O+,RJU8T7*[DNJW?HS^K/\`X;%_
M92_Z.9^'O_A967_QRC_AL7]E+_HYGX>_^%E9?_'*_E+_`.&$OVV?^C1_B1_X
M1=]_\:H_X82_;9_Z-'^)'_A%WW_QJO"_U-R[_H+7W+_,]?\`UGQW_0,_Q_R/
MZM/^&Q?V4O\`HYGX>_\`A967_P`<K7\#_M"_`_XEZ[_PC7P\^,GA37K_`,DR
MFRT;Q!;W4PC&`7V1NS;02.<8Y%?R:?\`#"7[;/\`T:/\2/\`PB[[_P"-5^@/
M_!M?^S)^T;\(?^"C$OBOXJ_`?QAX;TQOA[J=N-0USPY<VL/FM-:E4WR(%W$*
M<#.>#7#F/"V!P>"G6AB5)Q5[::_B=.#S_&8K%0I2H.*D[7U_R/W[+D*6Q]*_
M*G_@YW_;^;X0?L^Z;^QKX!UD1^(OB'F;Q&UN^)+31HFYC.#D&>8!!ZI%*,<U
M^H_BCQ'9^%/#]]XAU&&9X+"SDN)EMH6DD944DA44%F;C@`$DFOY<_P!N[P/_
M`,%!_P!N/]JOQ9^T9XK_`&2/B9%_;VHD:/82^#KW%E8)E+:W&8_X8U7)Z%BQ
M[UP\)X&AB<Q]M6DE&GKJUOTW^\[,_P`76HX+V=*+<I::+IU_R-G_`((U?\$H
MI/\`@IU\4/$EAXQ\3ZMX=\&^%M*234=:TJ*-II+R5@(;9/,!4902.Q(/"`?Q
M"OT7'_!I3^RH1G_AJ'X@_C;V`_\`:5?8?_!'3]B*U_80_8D\+?"[4M,6'Q/J
MUHNL^,Y2HWMJ-PJLT1/<0KMA'_7//\5?55;YKQ3F4L?/ZK5:IK1;:VZ[=3++
MN'\##"0]M!.6[;/R3_XA*/V5/^CH?B#_`-^+#_XU1_Q"4?LJ?]'0_$'_`+\6
M'_QJOULHKS?]9\__`.?[_#_([?[#RO\`Y]+\3\*/^"A/_!L]X)_9G_91\4?'
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M;^'<R6^AWWB71+BU%_I,F3"JO,J[WA8/&0.D?E>]?H:Q*J2!G`Z5\#CL*\#B
MYT6[V>_ET9]AAZRQ-"-2UN9?CV/Y@O\`@X9_Y2S?$O\`ZXZ5_P"FZWK]G/\`
M@W-_Y1%?#'_KYUW_`-/=]7Y1_P#!=_\`90_:A^)__!4'XA^,_AS^SMXVUW2+
MJ/3!;:GI/ABZN()2NGP*VV1(RIPP(.#U%?KA_P`$`_`WCCX:?\$LOASX(^(W
M@_4M!UBTN-;-WIFKV3V]Q#NUB\==T<@#+E75AD<@@U]MG]:E/A?"PC)-KENK
M_P!UGR>44JBXAKS::3O^:/LZFR1B2-HR2`PP<4ZBO@#[,_-W_@MQ_P`$1O#'
M[;_ARX^/_P"SSI-OIGQ8TRU)FA3;'#XEA49$,IX"SC&(Y>_W6XP5_!3X9_%/
MXS_L@_$GQ#IUE9W>CZI/I&I>&?%V@:G;O&)[:XB>WN+6>-L$%2VX9'RO&K#I
M7]AI&>*_.;_@M9_P1*\)?MR^$KCXZ?`BPL])^+6EVI8L(1'#XCB0?ZB<C[LP
M'"2GV5N""OVG#G$<</%83&ZTWHG_`"WZ/R_(^6SO)76G]9PNE1;^?FO/\S\,
M?^":_P#RD+^"'_95M!_]+X:_KDM_]2OTK^6K]@7]B3]L3P%^WU\(M6\9?LN^
M/M-L](^*6C2:E>WGA2Z2&V2._B+N\ACVA5`)+9Q@9S7]2EJ=T"D$=.,5IQQ5
MI5L71E"2:Y7L[]2.$Z52EA:BFFGS=?0DKSC]K_\`Y-6^)?\`V3S6O_2*6O1Z
M\\_:QL=1U;]F?XA:/I&GS7=W>>!-7@M;:W0L\LCV<@554<LQ.``.237QE!I5
MHW[K\SZFI\#/X]=/8)?0,W02KD^@W=:_KM\"?M?_`++-MX)T>VN?VD_`$;QZ
M7;JZ2>,+,,I$:@@CS.#7\L7_``PG^VR!Q^R/\2.G_0EWO_QJD/["?[;.?^31
M_B1_X1=]_P#&J_7<]RS`YXX<U=1Y;]GO;S\C\WRG'8S*7-*@Y<WJMODS^K0_
MMC?LI`9'[3/P]_\`"RL__CE8VO?\%!/V'O"\$MQX@_;%^%EFL0)8W/C[3TQC
MMS-FOY9/^&$OVV?^C1_B1_X1=]_\:JWH_P#P3V_;NUZX^R:1^QQ\3+B0D#9'
MX)OB>>G_`"RKY_\`U-RSKB_R_5GKOB;'_P#0,_O?^1^]'[7G_!R)^P#\`?#5
MY:_!_P`9'XG^)EB9;/3O#<+K9>9_"9+QP(PF>NS>3V%?@1^V%^UO\8_VX_V@
M=9_:#^-&II/J^L3*EM96N5M["V7B*U@4DD(@/&2222Q)+$GWGX)?\$"_^"H_
MQJOX(%_9SN/"MG*PWZAXSOH[%(ESRQC):;\!'FOU2_X)I?\`!N#\"_V4?$FG
M?&+]I3Q3!\1?&FGRK<:?8+9[-(TN=>5=8WRUS(IP0[[0.R`@-791J\-\,4Y2
MIU/:5&NCN_331(YZE//<^FH58\E/TT_'5LU_^#<?_@G?XC_8_P#V9K[XT_%;
M0Y+'QE\39(+I[&X3;+I^EQ*?LT+CJLC%Y)6'H\8."IK]'QTP.U-@@6")8EZ+
MTI]?G>.QM;,<5+$5?BE^'9?)'VF#PM+!8:-&&R"BBBN4Z`HHHH`****`.`_:
M+^%=Q\4/`4D>C1H-9TMS=:0[-CS'`PT!/99%+)GL2K8.VOB3Q/*)HFD,3HPR
MKQRIM9&!PR,.Q!R".Q!%?HRX)0@9Y&.*^8_VR_V;]19[KXO_``\TUIMXW^(=
M,@3+/@8^U1J/O,``'4<L%W`;@=P!\C1^-?&'PZUMO$7@+Q5J&C7V1YESIURT
M1E`Z!P#B0>S`BO0_!O\`P5:^./@-%L_B#X;TKQ3;H`&E_P"/.Y(]2Z*T9/\`
MVS%>4>+&5PTB,&5N0P.017F?B_HWT_QH`^_O`W_!9']EC6WCM?'EEK_ABXQA
MVNK(7%N/H\+,Q_%!7LG@C]M[]DGXBA/^$3_:"\,3O(0%AGU-+>3)[;)=K#\J
M_$KQ9U89."#D9KD$XD.`!\W84`?T5Z7XC\/ZY;K=:+K=I>1/]R2UN4D5OH5)
M!JX'!'`/Y5_/)X=\0Z_H;"?1=<O+-QT>TNGC8?BI!KT#PW^TW^TAX>54T/X_
M>-;5%/$<'BBZ"_\`?/F8_2@#]VPP/`!I:_%G1?V[OVPM/01P_M$>)75<;?M%
MX)?_`$,&NFL?^"B_[:,2`#XZZ@0#G][8VKGZ9,)R/K0!^P%%?"O_``3:_:Y_
M:(^.WQSO?"/Q4^(LNKZ=#X=FN8[=M/MHL2K+"H;,4:G@.>,U]U4`%%%%`!11
M10`4444`%%%%``0#U%8_@CP/H?P_TB30?#D!BM'OKFZ6$G(C>>9YG5>!A0SM
M@=AQVK6>2.,@.V,]*R_!_CGPGX_T^?5O!VMQ7]M;:C=6$\T*MM2YMIW@GCR0
M.4EC=#VRIIV=KA=&M0>1112`0J"<D`D="1054G)4$_2EHHLD"$V)G.T4>6G7
M:*6BC4=Q-B?W!^5!1",%`?J*6BE9"$"J.@'3'2EHHH22V`",C&*:(U`Q@8Q]
MWM3J*&D]P$V)_=%'EIUVBEHIZCN)Y:==HHV+_='Y4M%&^X7&F-,8$:_B*<!@
M444K(+A2%<]0,^M+1185D-\I.I1?KBG444]0L%%%%`!2$`]0#]:6B@&KB;%_
MNC\J4`*,``#T%%%+0`I"B,<L@/U%+13`38G]T4>6G7:*6BC4=Q/+3KM%&Q/[
M@_*EHH%<:8UR"%''M2A%5B0HY[TM%`:]PH(!&#110`T1H,808'M2[$_NBEHI
M+0-1-B9SM%&Q/[HI:0L!P33OYA<"B'^$4&.,]4'Y4N<T4`F```P!2,H8;2`1
MZ&EHH`;Y2#D(,X]*55"C@#\*6BAZ[@%%%%"=P&F-6SE1S2B-`,;12T4!=B*B
MJ254`GK00&&"/SI:*'J"T&B.,<!%_`4NQ!_"/RI:*6O<!-B#^$4;$_NBEHIZ
MCN)L3.=HHV+G(4?E2T4;B=Q-HZD"D,:\X49/?%.HH!:"*BIT4#Z"EHHHLEL`
M4444`%-$*`Y"#D\\4ZBC4.@WRH]P;8,CIQ3B,\<>^:**0DDA-@_NCVXH"J#D
M`4M%.R&%%%%`!2%0WW@#]12T4M&'0;Y:]-H_*G``#`%%%%K"LKA2%0>H!^M+
M13&U<38O]T?E1L3IM'Y4M%`";$'\(_*C:HZ*/RI:*`&F-&&&4'ZC-*(T4[@@
MSZXI:*+!HE8****`"BBB@`HHHH`****`"D=0P.?2EHH`^2/VP/V#KS7C=_$C
MX%Z=_I,C--J7AI,*LQ/+26^<!7/4QYVL>5P20WP'XYM;RQNI]/O[26WN()&C
MN+:>)HY(G4X*LK`%6!R"#R*_;.O%OVH?V'O@]^TS9/J&LVC:1X@5-MMK^FQ@
M2G'W5E4_+,GL<,/X66@#\8/%G#$'WKCE_P!8?]ZOI[]K+]@#]H?]G<W.K:KX
M7DUO0(22OB#1HVDA5/[TJXW0_P#`N/1C7S"AS(W^]ZT`:-C]S\*U+/I^-9=C
M]S\*U+/I^-`&G9_UK5@^Z/I659_UK5@^Z/I0!]=_\$>_^3F-1_[%&Y_]'V]?
MIC7YG?\`!'O_`).8U'_L4;G_`-'V]?IC0`4444`%%%%`!1110`4V21(U)9@,
M#/)KE/BM\</A;\$-&;Q%\5O'>E:#99Q%-J-VL9F;&=B*?FD;_94$GTKX+_;%
M_P""T6J36-SX2_95\,269=#&WC#7[7#KV)MK5N<^CRX`[QL*[<'E^+QTU&E&
M_GT,ZE6%)>\SV3_@JI_P4D\)_L8_"NZ\)>#]6@O?B-K=A(NB:?$V_P#LU&!7
M[;.!]U5R=BGF1AP,!B/5?^"?'PLUCX._L=?#WP3XF\XZNGAF"\UR2X'[Q[^Z
MS<W)<]V\Z5\GN:_&_P#8]^!?BS]MS]N'0-`\9:C>:RMQJG]M^,]4U"4RR2V=
MNZO)YC'KO8QP@=!Y@P,+7[[0JBQ(L2@*%`4`<`5Z6<82CEE&&$@[R?O2?X)?
MF<^'G*K4=1^B_4=1117@'85=7U6ST6PGU;4[R."UM8&EN)I3A8T4$EB>P`!-
M?//_``]T_P"":/\`T>_\.^?^IEAKV/XZ_P#)&O%O_8M7O_I/)7Y._P#!MG^Q
M/^R5^T5^Q'X@\;?'/]GCPCXLU:W^(-U:0:AK^BQ7,R0+:VS+&&<$A078X]Z]
M7`X+!UL!5Q.(;M!Q5E;[5^_H>=B<1B(XJ%"E:\E)W=^ENWJ?I=\*/V__`-B;
MXVZO%X?^%O[6GP\US4)VVP:;8^++1KF4_P"S%Y@=OP6O8!)&WW7!SZ&OSC_X
M*J?\$?O^";&D_L=^/OC5HOPFT/X;:]X3\-W.IZ+XD\-'["%NXD+0PO&I\N42
M2!8\;=_SC:0<5UO_``;Q?'OXO_'_`/X)SZ#K?QEU>ZU.]T37KW2-,U:_<M->
M6<!7RR[Y)<IO:(,>2(ADY%.M@<-++WB\/)\J:BU)+=JZLTVF.GBJT<5]7K)7
M:NFO6VJ>J/O"BC-%>2>@]#S[XH_M/?`CX)>,/#O@/XM?%K1/#^K^+KHV_AG3
M=5O4BFU24.B&.!3S(VZ6,8'=U]:]`C8L@8CK7Y/_`/!>[_E(K^Q%_P!C_/\`
M^G+1Z_5^/[@^E=^)P<:&$HUD[\Z;]+2L<>'Q,JV(JTVO@:7WQ3_4KZWJ^G>'
M]&N]>U>]CMK2QM9+BZN)FPD4:*69V/8``DGVKE?@5^T'\&/VE/!LGQ!^!/Q.
MT;Q;HD=Z]H^J:'>+/"LZ*K-&67C<`Z$C_:%'[1_'[/'CW/\`T)>J?^DDM?!/
M_!JQ_P`HTM4_[*CJG_I)8TJ6$C4P%3$7UBXJWK?_`""IB90QL*%M&F_N:_S/
MTJHHHKA.P*S/&/C+PK\/_#&H>,O&OB&STG2M+LY+O4=1O[A8H;:!%+/([L0%
M50"23P`*T9I/*B:3'W1FOS`_X+Q?M#^/?CWXZ\!_\$A_V:M1+>+/BCJ%O+XS
MGMP6&G:4')59=OW5;RY)7''[N'T<5V8#"/'8J-*]ENWV2U;^2.;%XF.%H.;U
M>R7=O9'Z$_`O]H[X'?M)^%Y_&WP)^+&@^+=(M[LVLNH:%J"3QQSJ`6C8J>&`
M93@\X8'O7<=>E?C9^S_H3_\`!"+_`(*H6/[.=UXAO#\#?CII]LF@ZIJ<V4LM
M4B"Q!G<X4,LKE'Z?N[J(G[M?LE&<H/I6F98*&#JQ=.7-3FKQ?==;^:9&#Q,L
M1!J:M.+M)>?^36J%HHHKSSL,SQ?XJT3P1X=OO%OB75H+#3=,LY+K4+VY;;';
MP1J6>1CT"JH))/3%>!?\/=?^":&`3^W!\.N?^IEAKM_V[?\`DS'XL_\`9-=;
M_P#2*6OSQ_X-Y_V%_P!CO]H#_@G98_$'XU_LU>#/%&N-XNU.W;5=;T*&XG:)
M'38A9P3@9.*];"8/!3R^IBL2Y6C)1M&W57ZGG8BOB%BXT*5KM-W=^ENWJ?H-
M\*/V_OV)_C;K$?A_X6_M9_#S7-0G;;!IECXMM&NI#_LQ>8';\%KV`21G@.#^
M-?G%_P`%6/\`@C__`,$V=(_8Y\??&S1OA/H?PUU_PEX<N=3T3Q'X:/V$"[B0
MM#"\:GRY1+(%BQMWY<;2#BNQ_P"#>;X\?&+X_P#_``3E\/Z_\:-4N]3O-'UV
M^TG2]7OW+37EE`R^6S,3F0H7:+<>2(ADD@TJ^!PSP#Q>'D^5-1:DENU=6:>O
MX!2Q=:.*^KUDKM737K;5/4^[:**4=?PKRD>B]$>9?'S]KS]F_P#9>.G-^T)\
M;?#O@Y=6\W^S#K^H);BZ,>W>$W'YMNY<X]179?#[XA^"/BIX-TWX@?#OQ9I^
MMZ+J]LMQINJ:9<K+!=1'HZ,I((-?DU_P<\^"=,^)7Q=_9B^'.MSRQ6>O^,;W
M3;N2`@.D4]QI\3%<]"`QQ76_\$&OC/XY_9=^./Q#_P"".W[0VILNM>`]4NM1
M\`33G`O=/<^;(D>>JE9%ND`[32?W:]^63QEDT<73E>>K:_NIV;7II<\A9E)9
MC+#SC:.B3\VKV?KK;T/U2)`&2<`=2:X?XZ?M'_`[]FKPK#XX^._Q6T+PGI%Q
M=K:V^H:YJ"6\<LY5F$:LYY;:K'`[`GM7;3<Q-_NFOPP_X*J>+O$O_!6#]LCQ
M[\*/`6M3_P#"J?V9?`>L:MKFHV3?NKK5XX&)4,/E8M-$L*GLL$[#J:X\JP"S
M#$<LWRP6K?;M\V]CIQ^+>#H7BKR>B7?J_DE=G[2?!?XX?"G]H7P1!\2_@K\0
M=*\3Z!<RR10:OHUTL\$DD;%74.O!(((/H:ZVO@+_`(-H?^44WA;_`+&;6?\`
MTL>OOVN?'X:.#QM2@G=1;5_1FV$K/$86%5JSDD_O5PHHI'944LQZ"N-Z(Z.I
MA?$KXD>"?A)X+U#XA_$?Q98:'H>E6S3ZGJVJ7"Q6]K$"`7=V("CG'/<UF?!'
MX[_"7]HGP5%\1O@K\2M&\5:'--)"FJ:'>)/"98R`Z;E)&5/!%?FU_P`%J/B]
MXP_;G_:F^'?_``1M^`NJR1G6=3AUCXK:E:'(L;%!YJ1.1QA8PTS*>K&W'4XK
MG?V'-3O?^",O_!577_\`@GIXIU"Z'PC^,++J7POU#49BR6MZWRQ0ESP6.UK5
M^[.L#<;J]Z&3\V`]IS?O6G-0[P3M?UZI=D>5/,91Q/+;W$^5R_O-7MZ=/5GZ
M\44R"02H)!W]J?7A'JO1A2,Z)]]P/J:6OG;_`(*C_MR:+_P3W_9#UW]H.\L(
MKW54E33O"VF3,0MYJ<P;RD;!'RJJR2L.ZQ-C!YK6A1JXFM&E35Y2=EZF=6I&
MC2=26RU9ZU\8?C[\$_@!X7;QE\:_BUX<\)Z8I(%[X@UB&T1R!G:ID8;F]ER?
M:OG"Z_X+N?\`!*BSU<Z-+^V'H1E#[3+'IMZ\6?\`KHL!3'OG%?+_`/P3E_X)
M,7O[;>E:;_P4%_X*M>(=4^(/B?QC;IJ?AOP9J=XZ:;I=A)\\!>!<`AE(981B
M-58;E9B<?H+;?L)_L8VGAX>$K7]E3X=KIPB\K[+_`,(78[2O3&?*S^M>I4H9
M3@Y^RJ2E.2W<>5)/K:]V[?(X:=7,,1#G@E!/:]VVO.S5C<^!7[4'[/7[2WA]
MO$WP'^-7AGQ;:1D>>^A:S#<-`3T$B(VZ,\]'`/M7>U\6>$O^"&O[(WPC_:_T
M+]K?]GO6?%'PZN-*W/?>%?".K?9]-U&4L"H=&#,L1^;?"I"/\O"X.[[3`Q7G
MXN.%C47U>3::ZJS3[=GZHZZ$\1*-JT4G?H]_/N%,N':.%G4'(]!3Z;.<1$US
M6N;L^=]3_P""L7_!.+1=2N-'U?\`;4^'MO=6D[P75O+XCA#1R(2K*1V((((J
M#_A[M_P3/[?MP?#K_P`*6&OSH_X(`?LE?LS_`+2WC7]HN^^/WP,\+^+Y=*^(
MJIILGB'2([IK=7ENRX0N#M!*@X'I7Z3C_@E1_P`$X/\`HR7X:_\`A)V__P`3
M7OX[`9/@,2Z$^=N-M5R]4GU]3R<-B,?C**JP44FWWZ.QZ!\`/VI?V?\`]J+2
MM1UW]G_XP:!XPLM*N5M]0NM`OUN$MY67<$<J>"5YQZ5Z#7"?`[]F;X!_LTZ=
M?Z+\`_A'H'A&SU.X6>_M=`TQ+:.>15VAV"``D#C)YQ7=UXE9T74?LK\O2^YZ
MD.?E]^U_(*X'X]_M-?`G]F+1++Q-\?/BSH7A#3M0NOLUE>Z]?I;QSS[2WEJ6
M(!;:"<>@KOJ_*/\`X.S_`/DT7X:?]E%;_P!(IJZLMPD<=C84).REU.;'8F6$
MPDZR5VD?JO:S-.I<].V1BDU"[CL;1[R:542-2TCMT4`9)HLO]6?]XU0\<?\`
M(H:G_P!>,O\`Z`:XDKRL=*E>"?D<O\"?VE_@;^TMI%]X@^!'Q7T/Q;8Z9?FR
MU&[T*^6>.WN`H;RF9<@-M*G'O7>U^5G_``:F?\FO?%;_`+*M+_Z16]?JG7;F
M>#C@,?4P\7=1MK\D_P!3GP6(EBL+&JU:Z"O&_C3^WS^QY^SEXS'P^^._[2OA
M'PIK36<=VNF:WJ\=O,87)"2;7Y*DJPSZJ:]DKR;XN_L+?L@_'[Q>?'WQO_9S
M\'^*]:^R);#4]=T.*XF6%"Q2,,X)V@LV![FN:@L-[7]_?E\K7_$UK>VY/W5K
M^=[?@<1_P]U_X)H?]'P?#K_PI8:&_P""NG_!-/H/VX?AT#GOXDA-?GG_`,')
MW[&/[*?[.G[*/@+Q1\"?V??"7A/4+WXHV]E>7N@Z'#;23V[6%[(8F90"5W(I
MQZJ*_0GP;_P2Q_X)T7?A#2KJ\_8M^'$DLFG0-)(_A:W9F)1<DDJ>:]FI@\DI
MX2%=\_OW5O=Z6_S/-IXC'SQ<Z/N^[;^;K?\`R/9_@O\`&_X4?M#>!(?B9\%O
MB!I?B?0+BXEAM]7T:Z$T$CQMM=0Z\$A@0?<5UE<O\(/@M\*_@%X+C^'/P:\!
M:5X:T*&XDF@TG1;);>WC>0Y=E11@%CR?<UU%>)/V?._9WY>E]_P/5CS<JYMP
MK@;7]ISX#7GQXG_9FM_B]H+^/;:T-U/X06^7[>D'EB02&+J!L96SZ$&N^K\G
M?!G_`"M?^)_^R<+_`.F:UKLP.$CB_:W=N2#E]UM/Q.;%8F6'=.ROS24?O/UB
MHHHK@.L*HZ_XCT+PSI$^O:_KEGI]E:(9+J\O;E(HH4'5F9B`H]R13/%/B72O
M!_A^\\3:]>);V.GV<MS>W$IPL44:%G<GL``3]!7XV_!O1OC;_P`'%_[3GB?Q
MS\5/'&L^&/V9_`6M?9=(\)Z1<FW;6IAAD61OXI"A621R#Y:R*B`$EJ[\!@5B
MXSJU)<M.'Q2_))=6SCQ.+]A)0C'FG+9=^[;Z)'WQ\0/^"U__``3`^&>KR:'X
MC_;)\)SW,3['_L:2748P>_[RTCD0_@:[3]GW_@I9^PU^U'J\?A_X(?M0^$=9
MU.3'E:/_`&B+>\E_W()]DC_@IQWI_P`)?^":W[!_P8\-0^&OAW^RCX%M+>*,
M)YMUX<@NKB0#N\TZO*Y/<LQ->1_M@?\`!";]@G]JJUBU+1?A_'\-_%-M=1S6
MOBKX?V\5A.NU@6#1*OE29&<,5W*<$-V.ZCD<GRWJ1_O.S7_@*7ZLSE_:<%S6
M@_+5/[]?R/L]9(W^XX..N#2USWPK^'UM\+/A_I'P^M/$NL:Q'H^FPV::IX@O
MC<WMTL:[1)/*0#)(>I;`R>U=#7E-)2:1WIW284$@#)-%9'C_`,;>%_AOX(U?
MQ_XTUJ#3M(T339[[5+^Y;$=O;Q1L\CL?0*I/X413E))#T6YQOQA_:Y_9L^`W
MC'1/`'Q>^.OA?PUK7B,@:'I6L:K'#/>DN(QL5B"078*#W/%>CI)')PDBMCK@
MYK\&_#G['?Q9_P""\T_Q\_X*"Z[<:CIT=I$VD?`;3&F\M6DM'\U4;GD>6HC8
MC@S74C?\LZ_1/_@AK^WK>?ML_LBV^D_$.\9?B'\/&30/&MM=<7$DD0*PW3J>
M09%4[N!^\23VKVL?E$,+A?:4Y\TH-*HOY6U=?+IZGE83,7B:_+*-HRUB^]M_
M\_0^TZ***\0]41CA21Z=ZX#XC?M._`?X2>/_``_\*/B3\7M!T3Q+XK<1^&]&
MU*^6*XU*3>$VPH>7.\A>.Y`KOY/]6W^Z:_)G_@M#_P`ID/V-O^P_'_Z=(*[\
MLP<<?BG2D[)*3^Z-SCQV)EA*'M$KZI?>TOU/UF7.T9ZXYI:**X#L"BB@]*`,
MKQ?XT\*>`]`N?%GC/Q1I^D:581&2_P!2U.]C@@MT'5GD<A5`]20*^6O$G_!<
MW_@E?X7UU_#VH_MC>')9TD*&33[:ZNX,Y_YZPPLA^H;%?%O_``<5^.K_`,3?
MMD_L]_LN?&'QMJ'A_P"#7B"\M[WQ7<P7+0PSN;X0RF1^G[J':1G.SSRWO7Z-
M?"O]@/\`8*\)_#73_#'P\_9B^'CZ%+8(+=U\-6ET+J)D&'::1':;<#G>6).<
MYKVOJ6"PV#I5\1S-U$VE%I)).VK:>OE8\SZUB<1B)TZ%ER63O>[;5]DUH=A\
M`/VI_P!G?]J+PT?%?[/OQK\-^+[*-MMP^AZI',]NW998P=\1QCAP#WZ&O0J^
M</V=O^"4?[%/[*O[16M?M-_`KX9R:#X@UJT^S-9VNH2K86:$?O/(M@=B;S@G
M.X#'RA<G/T>#FO,Q"PJJ?[.VX^=K_AOZG=1=5T_WJ2EY?GJ%%%%8&H4444`%
M%%%`!1110`4444`)(BRH8W&0PP017SY\?_\`@F+^R9^T#)/JNJ^!?[`UB<EF
MU?PVRVTC.?XG3!CD)[DKGWKZ$HH`_+OXN_\`!#WXS>%99;[X-_$G2?$MKRR6
MFIH;&Y`],Y>-S[EE^@KY]\=?L9?M2_"EI/\`A-?@;XA@BC/S75M8-<PD>HDA
MW+^9%?N-@'J*0JIZJ/RH`_`**WFMI3!<0R1R*Q#1NA#+]1VK2M^1@$'CM7[J
M>)/AWX`\9(8_%_@?1]54C!&HZ;%/D?\``U-<1K/[%W[*&N2>9??L\>$<]OL^
MBQ0_^BU6@#X;_P""/[^7^TOJ1(Z>$+G.>/\`EO;U^ESW:KCY"2>U?D#_`,'&
M6AP?L0_#OX7^,OV0]1U/X<:IK?B*_L]5U#P=J]Q8RW4`MT<1.T<@)7<`<=,@
M5^</@C]L_P#:_P!>?&M?M6_$RY$@`D67QWJ!#?4>=BOJ,MX6KYE@5B5423OI
M9WT9X]?.*5#&/#N+NNOJKG]3?VV(#+<?4U4O_%6@Z7;M=ZEJ=O;QIR\D]PB*
MH]<DU_.!X5^*GQ3\2;6\3?$[Q'J.[AOM^NW,V>G7?(<]!7K'P^T71]4NDN=2
MTBVN'SGS)X%=L_4BM9\*.C\57\/^"=4,8JBND?MGK_[7'[,GAF0P:Q\>/"<<
MH.#"FO6[R?3:CDY]L5D+^VK\&]4(3P39>)?$;G[@T?PS<[&^DLR1QX]]V/>O
MS\^#UM;VIBBM8$C5<`+&@4#\J^I_@YR\)/\`=_I7E8K`4,)KK+YV.F,Y25SO
M/&/[67Q*@MVF\)_`-K?`.'\5^(8;=@?[WEVJW&0/0LN?45X%\5_VF?VG=?@D
MMKKXJ0:)`P/[CPEI2VS`?W3-,TTAQTW(8_H*];^*8&^08'>OG?XD?ZR7ZFM<
MOITI->ZONO\`F34V/G[XEVQO=9G\1:M=7-_J,X(GU+4KR2YN''7!ED8L1[9P
M.U>)>/94A6224D*,DG'^<U[A\2)$C21W=5`5B69L`#'K7O/_``3._P""?,OQ
M,\2:?^U+\:/#S)H.GW*S^#]%O8\'49E(9;Z1#_RQ4\Q*?OL-Y&T(6^K>,H8#
M#.K-V2V7=]CCE3E4GH>U_P#!(K]B.Y_9D^"\_P`0?'VE&W\:^-1#<ZG!,GSZ
M=9J";>S/HPWL[C^^^.=@-?7ZC``)[4B1HA.Q`/H*=7Y]B<34QE>5:;UD>A3@
MJ<%%!1116*W+.2^.O_)&_%O_`&+5[_Z3R5^)7_!"/]@?]I/]J+]DO6O'OP@_
MX*.^/_A%IUKXUN;.7P[X5M?,MYY5M[=C<,?/C^<APIXZ(*_;KXRV-[JOPK\2
MZ3IMH\]S=:!=Q6\,8RTDC0NJJ/<D@5\.?\&W7[/?QQ_9J_8G\0^!/CY\*]:\
M):Q<>/[J\@TW7+,P2R0-;6RK(`>JED89]J]W+<7+"9-7<&N9RAO9][Z.]_N/
M(Q>']MF-%M:6EU:_EZJQGZG_`,&]MM\9M5L[C]M#_@H;\8_BQI]G.LJ:-J>J
M_9[9B#TVL\I4')'RE2`3@CK7WI\&?@]\.?@!\+]&^#GPE\*6FA^'=`M/LVEZ
M78IMCA3<6/7DDLS,S')9F))))-=,O(!I:\W$X_&8N*A5FW%;+9+Y+0[J&$P^
M'DW".KW>[^]A111GG%<9TVN?D#_P<>^#;SXB_MF?L@^`;#Q9?Z#/K?B>_L8=
M:TJ39<V#2WVDH)XF[2(3N4^H%>[I_P`$._C`R@C_`(*__M&#T'_"2G_XNN:_
MX+._LY_'GXU?MU_LE^./A+\(M=\0Z/X,\9RW?BG4M+L&EATR$W^F2!Y6'"C9
M%(WT0U^E-NP:%6!ZBOH\1F-;#97A8T)+:5]$]>=]T[:'B4<#2K8[$3JQ?Q1M
MJU]A=F?FS\8_^"*WQ;\,?"'Q5XEN/^"M/[0FH)IWAR^N7L+SQ$6BN1';NQC<
M;N5;&TCT)I/^#5L@_P#!-356`P&^*>J<>G^B6-??WQZTK4==^!GC31-'LI+F
M[O/">HP6MM$N6ED>VD544=R20!]:^,/^#<7X`_&O]F[]@34?AY\>OAAK/A+7
M'^(NHWB:7KEF8)F@>VM%60*W.TE'`/\`LFH>/K8K)JL:TDWS0MLOYNU@6%IX
M;-J;IIV<97W?\O=GWW1117SY[9YU^U/^T?\`#_\`92^`?BSX]_$RZ\G2/"^C
MRW<RA@'N)`O[N!,]7D<K&H_O,.G6OQ:_X)&_\%!?V*_#/[2GQ0_X*(?M^?'R
MUT_XG>,M5>U\/:2VCWES_9=@0K.R-%$ZJ"!%`@!R$@/]^OJK_@MG\&_VQOV_
MOVD?AM^P=\)/A3XFL?A:^KVNH>/_`!Z;)UTYG))V^8?E<00AF`Z-+(J]5X^\
MOA]^QY^S%\/O!6F>!=$^`7A`66D6,-G:"?PY:R/Y<4:HI9V0EFPO+$Y)Y-?1
M8>I@\NRRU2\IUM^5I.,4]$WK\3W7:QXM:.)Q>.O"RC3VNG9R:WZ;(_,?_@LQ
M_P`%"_\`@D[_`,%!_P!CS4/`O@[]IFT/CCPW/_:_@>X/A^_0F[08:W+M``JR
MH2F20`VPG[M?5O\`P0I_X*!I^W;^QWIP\7ZLL_COP/''HWBX2/\`O+DHN(+P
MCOYT8!+?\]%D%?4;?LU_LZ-PWP"\%?\`A+6G_P`;K\T?$G[*'[1__!-W_@LI
M;_M'?LC?`SQ!X@^#_P`5D,?C[1O"FF-)%I!FD'GMY:#"!)MERF`/E:5!@&JI
M5<!C\!+!P3C*/O0<I)Z]8WLK<VZ\R90Q>%QJQ,VFI>[*R?R;U>VWHS]9**CM
M7\R!9"3EE[]:DKYJ]SW'8\F_;M_Y,R^+/_9-=;_](I:_(_\`X(N_\$_/VI_V
MB_V%;?XE?!K_`(*9?$3X6Z<_B+4K>#PGX=M2UFDT93=+D7"'+DC.%XK]>_VS
M-`UOQ;^RG\2O"7AC2Y[_`%/5/`.KVFGV%K&6DN)Y+214C4#J2Q``]Z^9?^#>
M[X'?%W]GO_@GG8_#7XY_#35O"^O1^+=3N7TG6[,PS+%(Z;'VMS@[3BOH,%BY
M83)*W(US<\='9Z6?1GDXG#^WS6GS)VY9;-K73L?GA^RM^S?+^U'^WCXA_8+_
M`."Q_P"TM\5=4\8>'M0\WPCH=[XO<Z3X@1`7^0RAF4O'^\385+(6&59<']T_
MA!\+?A]\$_AIH_PI^%?A*TT+P]H5F+72]*L8]L<$8).!ZDDEB3R22222:^,_
M^"U7_!,C6/VP?AK9?M`_L^`Z5\9OAPPO_"6I:>WE7&HQQOYILRXY#@C?$>SY
M'`=B/8O^"9W[0?[1GQW_`&<M,G_:Q^!?B/P+X_T7;8^(;76]-:VCU%U7Y;V#
M/!608+*/NON'3!-YKB)9C@X8FG*R6DJ>BY9?S)=5+OT>A.`H_5*\J4HW;U4M
MVUV;[J_W'T=2CK^%(/K03@9-?/=3V&NA^37_``<9?\G1?LA_]E+?_P!+=-KH
M_P#@OM^SYXZ^$7B3P#_P5J_9WL3'XP^$NIVR>*%A4_Z;I1DPK2;>653(\+]_
M+G;.`E:G_!=;]FWX_?'K]HC]F/Q'\&/A#KWB:Q\*>/6O/$5UI%@TJ:?`;NP<
M22$?=7;&YS_LFOT.^('@7PE\4/A]J_P\\<:)#?:/KNERZ?J=G<("L]O,ACD0
M^Q5B*^DCF$<)A,%46J2FI+NF]5\T>%]4EB:^*B]+\K3\TM']Y\1?M\_\%=/`
M7PV_X)9Z=^UE\$M81M=^*.CK8^`+5)%::WU"9&29B%YW6N'W#_GI&JG[U<5^
MRU^P;+^P_P#\$1OBG!XUL"/'GCCX;ZSKWC6YG7,R3R6$ACM6)Y/E(<$'_EH\
MA[U\[_L*_P#!%#]HCPW_`,%((/A[^T)9:S?_``+^#'B&[U[P'-JBE[#59IY(
MY+>.%6RI.Y(GF7&,P%3]_-?J[^W3X3\0>,_V-/BCX(\&:'<:EJNJ^`-6L].T
M^RA+RW$\MI(D:*HZLS$`?6KQ=3"9<Z>%PL^92E&4FNU_=3]%J_,,/&OBXSKU
MXV:3BEYM>\_F]%Y'R_\`\&T/_**;PM_V,VL_^ECU]^U\3_\`!`/X+_%O]GW_
M`()P^'OAC\;?AUJWA?Q!:^(-5EN-(UFT,,\<<ET[(Q4]`5Y%?;`Y&:\G.91G
MFM:47=<S_%GH9:I1RZBI*SY5^""O(OVY/VM_`_[$'[,WBG]HWQ\8Y+?0=/+6
M%DTNUKZ\?Y8+9?=Y"HR.@R>U>M7+,EN[*>0IQS7Y8?\`!5SX`_M:_P#!3']O
M/X;_`+'UE\)_%6C?`WPMJ"7WC#QI-9/%9:A.R[Y2DAX<I"##&?\`GI-(>@S4
M970HXK%I59)05W*^FBU:7=O;0K'5:U+#/V2O)Z+U??R/G?\`X(K?M\?L(_`G
MQ!\1_P!LK]M[]I&UC^,7Q*UJ87$,FB7LQT^QWB1E5HXG4>;)@[0QVI#$..17
M8?\`!;?]O3_@F!^W5^S/:ZK\%OVFK;_A9_@+54U?P3+%H=_#).VY1-;>:\("
M;E"R*20-\"=`2:_6CP_^RK^S7X?TJWT33_V?O!4=M:0)#;I_PC%J=J*-JC)C
M]`*LW?[-?[/#PE4^`W@Q2>A7PO:`_P#HNO5><8+Z^L6J<^9;>\K62M:W+M;2
MQYT<MQGU3ZNYQY7OH[WWO>^]]3PO_@CQ^WOIO_!0+]C;P]\2=3O8CXNT2,:1
MXVME;YEOXD4&;'99DV2CL"Y7^$U]6U^3_P`(?V5?VF/^"7W_``6/UG6_V??@
MCXCU_P"`?Q<5&UD^']->:VT":9B5+A.$$%QN(P.+>8CJ*_5RT8O"'))STS7G
MYMA\/2Q/M,.U[.:4EKJK[I]K,[\OJ5YX?EK+WXZ/S\UZHDK\N?\`@ZY\%^*-
M<_8;\$>,])M);C3/#OQ+@EUF*,$B-);.YCCE;T4.1'GUF'K7ZC5QOQ]^"/P\
M_:0^$VM_!#XK^'(M5\.^(K%[35+*;C<AY#*1RKJP5E8<AE![5AEV,6`Q].N]
MHO\`#K^!6.H?6L).C>W,C,_9-^)W@GXO?LV>`?B'\.;N*XT75_!^GW&GR0$;
M50P(/+('W60@H5_A*D'D5Z*#FOR<^%_[.7_!5O\`X(N:_?\`A?\`9A\'I^T'
M\#+B]EN;'PH+_P"SZQHH8EG\M2#ALY)$8D20Y8I&S&O5K/\`X+QZ_!9_8?$'
M_!+#]IF#6E^1[*V\#"6W\S!X\\NIQG'.RNNOE-:K5<\*U4@]FI*__;R;33[G
M/2S",(*.(3C)=T[/T:NF?H;17YK^#/BI_P`%K_V]?CUX9\5>$_`#?LT?"O0=
M0%UJ'_"3".\U77(SP8WMG7)!4X"%8T4G=O8JH'Z16<=S&I%S+O.`,YZGU]JX
M<7A981QC*46WND[V];:?<SLH8A5[M1:2[JU_3_@V)J;/_JC3JCNG6.!G8'`]
M!7*MS9['X*_\$<_V$?&O[8_Q`^/>H^$_VROB3\*TT/X@&*>W\!:G]G34#)-=
M$/-R,E-I`]F-?=`_X(<_&#O_`,%?_P!HS_PI3_\`%U\H?\$U_%O_``4$_P""
M:OC?XQ0R_P#!+?XI>-[;QSXU?4+&\TVV-LB1QR3A3\T;[PPE!!&.GO7U>/\`
M@KI^WS_TA'^,?_@8/_D>OMLTJYM/'2EAI1<':VM/LK[N^_<^7P4,NAAE&NI*
M5W?2?=]M#ZQ_8]_9O\0?LL?!^'X5>)/CSXL^(]Q#?SW/_"2^,[OS[YUD;<(B
MV3\B=!]:]5'`Q7SK^PC^U[\>_P!J:X\21_&W]B7QE\'_`.QDMCI__"67'F?V
MGYADW^5^[3&S8N?^N@KZ*KX_$JM&O+VOQ/5V::_#3[CZ/#RI2HQ=/;9:-?GJ
M%?E)_P`'9T<S?LA?#:586,<?Q%/F..BYLI\?R/Y5^K=?.O\`P5!_8-T7_@HG
M^RAK7[/U[JD.FZFTL>H>&M7G4LEEJ$.[RV<#DQLKO&V.=LA(!(%=>48BEA<R
MIU:CM%/7[K7^1AF5&5?`U*<=VM#WSP_J-IJVF1:G83+)!<1K+#(IR'1AD$>Q
M&*J_$&YBM/!.JW$\@1$TZ=G<GA0(V))_`5^87[,__!1#_@HE_P`$_P#P'IO[
M-G[=7_!/;XE^,X_#-JFGZ1X\^&EE_:OV^UB&R(R*ORNP0*-V]6(`W*#DD_:8
M_P""B7_!1+]O_P``:E^S3^PM_P`$]/B7X*3Q1`^GZOX]^)UF-*%A:2`I+L5O
MD1F0D;_,9@"=J%L$=/\`8N*5:_-'DO\`%S+EMWWOMTW,(YE0C02L^:VUG>^U
MO^#L._X-2MY_97^*ERL9,4OQ7F$<N/E8BQMCQZ\$?G7ZIU\X_P#!+G]@W1?^
M"=W[)NA_`*PU2#4M4\^74O%&KPQE5O=1F"^8R`\[%"I&N>2D:D@$XKZ.KGSC
M%4L9F=6M3^%O3TV-\NH3PV"A3GNEJ%%%%>:=I^6/_!UQ_P`F8_#G_LL-I_Z;
M;^OTY\"_\B3H_P#V"[?_`-%K7Y\_\'(_[.WQU_:7_99\">#?@!\)]<\7:I8?
M%"WOKVQT.R::2&V6PO(VE8#HH>1%SZL*_0?P3'+#X.TJ">)XWCTZ%)(Y%PRL
M$`(([$$5Z^)E!Y-AXWU3GI_X">9AXR69UI6TM']34HHHKR#TPK\G?!G_`"M?
M^)_^R<+_`.F:UK]86Z8'Z5^:WA3]FGX_6G_!R;X@_:7N?A%KJ>`+GP(+2#Q<
MU@WV%YQI5O%Y8EZ;MZ,N/537LY/.$%B.9VO2E;S>FAYN8Q;=&W_/Q?DS]*J*
M**\8](\H_;E\&^)?B-^QW\3_``!X,C=M6UCP#J]IIR1#YGF>SE5$'NQ(7\:^
M&_\`@U@^(7@O6?V$=;^&.FF*'Q!X;\<WKZ[:,0)=MPD312%<YP0C)GUB8=J_
M3IXXY!M=`P/4$9K\S/VG/^"4G[5'[*W[4VJ?M]_\$C?$VF6&KZW*\OC+X5:K
M,(K#6`[;Y1#DJ@#M\_ENR;'RR..$KV<NJ4:N!JX&I-1<VI1D]KKHWT3/+QE*
MK#%0Q,(N2BFFEO9VU7>Q^FE%?G3X?_X+<?M"^`XE\._M2?\`!)KX[Z/KL(VW
M1\$Z`-7M9''5HW)C&TG_`&F]B>_/?%+_`(*(_P#!5']M?1I?A3^P)^P+XT^&
M@U9?(NOB/\5-NG'38VX,D4+`X<#G<#(P[(3@C..38U/W^6,?YG*-O6]]?D:O
M,L,](W;[)._W6T^9^F]%<!^S!X(^-?PY^"&@>#?VB?BS%XX\8V-BJ:WXE@TY
M;5+N7GE8UP,`87=@%L;B`3@=_7F3BHS:3OYG=%MQ3:L-FD$41D(Z"OR-_P"#
MF3]OK3]`\.>'_P#@GMX(\:VVE7WC.2WO/B!JSL[)INE&4"&&3RP6Q(ZM*Z@;
MO+B'!#BOU2^+7B^\^'_PSUSQMIWA/4]>N=*TR:ZMM$T:W,MW?R(I98(D'5W(
M"CW-?FC_`,$??V`?C1\3OVB?B?\`\%$?^"C?P:EM/&'BO6)++PYX6\7:6K?8
M;4[2\HAE!"J$$5O%W"12?WJ]C)OJ^'G+&U]53VCUE)[:>6][=CS,R=:M&.&I
M:.>[UTCU^_9:G=?LI?\`!7__`((O?LE?L^>%_P!GGX<_M.0)I/AG2H[2&1O#
M.H*]PX&9)WQ;\O)(6=CZL:^&[W_@HG^R/^R/_P`%E8OVM?V1?BU#KOPO^*J&
M+XHZ7;Z?<VZV$T\H\Z?9-&@;$NRZ!`/_`"V7C=S^XH_9K_9T`P/@%X*_\):T
M_P#C=>*?\%"/^":7P%_:W_9-\6?!7PU\+_#&@:[>V1N/#FLZ=H5O!):ZA%\T
M+;XT#;2WR,.Z.PKJP.897#%2YX3M5NI7DFM>MN5:K<YL5A,PE0C9QO"SC9-.
MZZ;]=CZ5T75K'6=*M-4TNZCN+6ZMDFM[F%PR2(R@JP/<$$$&K=?#7_!"+Q3^
MUWH_[*J_LZ?MD_!CQ3X:USX>2C3]!U7Q!8ND>JZ6<^2J2'AVAP8N/X!&1GDU
M]RBO#Q=#ZKBIT;WL]UJFNC5CU\/6^L48U+6;Z/IW0DG^K;_=-?DS_P`%H?\`
ME,A^QM_V'X__`$Z05^LLO$3'_9-?E=_P6]^#/[4NM?M]?L\_M)_`#]F3Q7\1
MM.^'<CWVKVOANR9SNCO8I5A+A6$;,JG!(_E7I</.$<R?,TKQDM=-XM+<XLXC
M*6"=ELX_^E(_5.BOSY'_``5U_;Y`_P"4(_QC_P#`T?\`R/7K?[%O[=_[3O[2
MWQ9N/`?QB_X)U_$#X3Z9!IDETGB'Q/<[[>652H%N!Y2_,0Q(Y_A-<M7*\91I
MN<N6R_OQ?X)W-Z>/PU6?+%N_^&2_-'U7110>G%>>=AXY^V-^PK^SA^WC\-%^
M&'[1W@&'5[."0RZ;?12&&\T^8C!E@F7YHR1P1RI[@CBOAZ3_`((5_MB?LI64
ME[_P3D_X*@>,/#5K`Y>R\&^,(C<:>S<D*S(3'C/'_'L3SFO=?^"DGQ'_`."M
M/P3\<^&/BE^Q-\-O#?COP%IF7\6>#47&LWIPP;#.<&,`@KY/[P,!N5UR*\X@
M_P""[GCN311IM]_P2D_:/7Q.NU!I<7@XO9F;T-T2&"Y[^5TKZ#`+-:6&7U><
M90EJXMQ:7K&6WR^\\?%/+YUY.K%J2T4K25_1K<Y[]@/_`(*K?M=^'_VXU_X)
MG?\`!2WX>:39>.KF)CX?\7:"HCAU$B)I4#HO[MUD1'*RQ[?F78R`@D?IL@QG
MZU^7W[&'[$?[9/[77_!2*U_X*J?MX_#FV^'=OX>L19^`?AZMR);Q$6*5(FG(
M^ZJ>=+(=V&9W^ZJC!_4(#'%<V<K#+$0]DDGRKG4?A4NMO+;;0WRV6(=.7M+M
M7]UO=QZ7_$****\@]$****`"BBB@`HHHH`****`"BBB@`HHHH`****`/R*_X
M.U_^2*?!O_L<+_\`])4K\B/AG_K$^@K]=_\`@[7_`.2*?!O_`+'"_P#_`$E2
MOR(^&?\`K8_H*_7>%_\`DGZ?K+\V?#YA_P`CR7R_(]_^'_W4^HKZ`^%_6/ZU
M\_\`P_\`N1_45[_\+^L?UIXOX3W,/\)])_";_61_45]2?!O[\7^[7RU\)N)$
M)]J^G?AAJVDZ%IQUK6]2M[2SMHP]Q=74ZQQQKZEF(`'N:^&S;73J>I2U5CH?
MBF"9)/QKYP^+.I6>F*\UU-M+R^7%&JEGE=CA41!EG8G`"J"2>`,U[_J47Q!^
M.%\;/X->#WN;&0D-XKUA'MM,5>/GBR!)>#T\H>6W_/5:],^"/[''P\^%>J0^
M-O$%Q+XE\5!&/]N:E`@%J6^\MK"HV6R=1D9D(.&D>N'#XFGA87GOVZ_\`IIR
MT1\\?LJ?\$Z=0\<:U9_%K]I7PXUOI4<JS:5X*NA\]P0<K-?`'`7H1;9.?^6F
M>8Q]RVMK;V4"VUK$$C485%Z`>@]!3HXUB01J3@>M.K@Q.*K8NHI3>VR[%TZ:
MIK0****YRPHHHH`:\2.<LO/KFA(8HR2B8S3J*5D`4444P"C'.:**`(C9VY8L
M8\DG)Y-2*H4;5&`*6BE9`(RAE*L,@CFDCACA&(UQGKS3J*87TL%%%%`#&@B9
M_,*<^N:>!@8%%%`!41L[8MO,0S4M%*R8")&D8VHN`.@I>M%%,!CV\,AW.F3]
M31';Q1'*+U'/-/HH>H7&O%'(GENN1Z4U+6",Y1,8.1R:DHI<L>P!00&&"***
M8$9M+=B&,>2.ASS2F"(QB(I\H&,4^BE97`C%K`&#[.0<@DGBE>"*3.],YZ@F
MGT4));`,CMXHL^6F,C'7M3^E%%"26P=;@0",&HS:6Y(;R^A'<]NE244P``#I
M1112LK6`8UM`S^8T8R#D'WIR(L:[4&!2T462`*,444P(S:6Y?>8\G.<DF@6M
MN%VB,8'09J2BDTF#U&+;0J<A/U-/HHIV`*21%D0HXR#UYI:*`(_LMOWCS]31
M]DM_^>0J2BE9`-CACB_U:XIU%%,`H(#`@C@]:**`(A9VX&%0CC'#&E^QVY()
MCZ=.34E%*R8K*]Q%147:HP!2T44QA1110!&UK`Y)9,Y]SZYIZJJ+M48`I:*+
M(=VPHHHH$%,$$0E\X)\WKFGT4K*X;!1113`*;)$DJ[9%R/K3J*!-)[D9M+<C
M;LX]`QH^RP#^#_QXU)12LAAC%%%%,!'19%*.N0>HIBVL"$%$P1TY-244`%-D
MACE7:Z\#T.*=12:3W`CCM+>%MT:$'_>-2`8&!113`"`P*D<$<TPVT#')CS^-
M/HI63`C^RV__`#R%*D$49RB8_&GT465[@%%%%,!LD4<HQ(N:;]DM\Y,>>>Y-
M244":3W(Q;0!@XCY!R.>]2444#"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`_(K_@[6_P"2*_!H?]3AJ'_I*M?D1\,Q^\C/L*_7;_@[8)'P4^#>
M#S_PE^H$9_Z]4KRW_@DA_P`$&M=^/_@?2_VAOVK-5O=!\*ZC$ESH?A2R_=WV
MJ0')6::0C_1XF'W0H+L#G*<9_4,FS#"Y=PS3J5I65Y>KU>Q\=BL/4Q.>S5-7
M:2^6A\N?#**;4KVVTK3K>2XNIVQ!:V\;22R'T5%!+?@#7V5\!_V*_P!KKQI'
M#/H?[//B&"&0`K<ZY`NFQX]<7)1R/<*:_6+X&_LP?`;]F[2?["^"?PIT3P[;
MM#LFDL+-1-/R.9)3\\IXZL2:[[8N<[!Q[5\YC.*9U;JC3LN[>OW(^CHX-P7O
M,^&_@[_P3:^.+&&?Q_\`$?1?#D*@"6VT:U?4+@C/:6411QM]8Y!FOHWP#^QE
M\%_`]S;ZKJ%A=^)=2M65H-1\47/VMHF'1HXL+#"V>\<:FO5U15.0BCZ"EKYV
MMC\57;YI6]-/R.N,.49%"(>%Q@```#&*?117(6%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`?#W_!63]E#3OVROVC_`-F/X1>([$7.A0>.
MM3U?Q'`P^62RM;-97C;V=@D9_P"NE?;=C8VFG6R6=C;+#%&@2..,855`P`!V
M`'%4]0\(^'M4\2:?XOOM-234M+@GAL+L_>A28QF51_O>4F?]T5I#D5TUL3.K
MAZ=)O2%_Q;?]>AC3H1A5G42UE^F@4445S&P4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
+%%%%`!1110!__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
